Ocular Manifestations in Pediatric Tumor Suppressor Gene Mutations: A Case Series and Literature Review of RB1, NF1, NF2, VHL, and TSC

Ocular Manifestations in Pediatric Tumor Suppressor Gene Mutations: A Case Series and Literature Review of RB1, NF1, NF2, VHL, and TSC | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Ocular Manifestations in Pediatric Tumor Suppressor Gene Mutations: A Case Series and Literature Review of RB1, NF1, NF2, VHL, and TSC Aoxiang Wang, Chanyuan Wang, Wen Li, Jing Qiao, Yulin Luo, Yu Tian This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-5838014/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 10 May, 2025 Read the published version in BMC Pediatrics → Version 1 posted 6 You are reading this latest preprint version Abstract Background: This study explores ocular manifestations in children with mutations in key tumor suppressor genes (RB1, NF1, NF2, VHL, TSC1/2), which are linked to common pediatric hereditary cancer syndromes. Mutations in these genes often lead to ocular lesions, particularly in the retina and uveal tract, including the choroid and iris. The expression of these tumor suppressor gene mutations in the eye has been a topic of interest for ophthalmologists and other healthcare professionals. We have summarized the ocular presentations of these common tumor suppressor gene mutations in pediatric patients. Methods: We reviewed 11 representative case reports, documenting in detail the ocular manifestations and progression of each case. These case studies were analyzed in conjunction with a detailed search of the relevant literature to identify specific ocular features associated with each tumor suppressor gene mutation, as well as potential underlying genetic mechanisms. Results: Our review indicates that children with mutations in RB1, NF1, NF2, VHL, and TSC1/2 exhibit a diverse range of ocular manifestations, with the specific features varying depending on the type of mutation. Early detection of ocular symptoms is crucial, as it allows for prompt intervention, significantly improving both visual and systemic outcomes. Additionally, these genetic mutations are frequently associated with systemic syndromes, emphasizing the importance of recognizing ocular symptoms and providing timely ophthalmic care and follow-up for early diagnosis and effective management. This highlights the critical role of a multidisciplinary healthcare team in managing these cases. Conclusions: This study highlights the significance of regular ophthalmic evaluations for children with hereditary cancer syndromes associated with tumor suppressor gene mutations. Early detection and timely intervention are essential for preserving vision and supporting overall development. Given the complexity of these conditions, it is vital for both ophthalmology and other medical specialties to closely collaborate and prioritize these patients. Future research should focus on larger cohort studies and the development of tailored strategies for managing specific gene mutations. tumor suppressor genes pediatric oncology ocular manifestations retina and uveal tumor early diagnosis Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 1. INTRODUCTION Pediatric patients with mutations in tumor suppressor genes, including the retinoblastoma susceptibility gene (RB1), neurofibromatosis type 1 (NF1), NF2, Von Hippel-Lindau (VHL), and tuberous sclerosis complex (TSC), often exhibit distinct or indistinct ocular manifestations that are essential for early diagnosis. These mutations predispose children to both ocular and systemic tumors, leading to complications that can severely affect vision and quality of life. The eye space caused by the mutation of these tumor suppressor genes has accounted for the majority of space-occupying diseases in children's ophthalmology. Understanding the unique ocular manifestations in children provides critical insights for early diagnosis and potential systemic screening. Regular ophthalmic evaluations in genetically predisposed children can facilitate early detection of eye-related abnormalities, ensuring timely intervention before visual and systemic complications arise.[ 1 ] Retinoblastoma (RB) is the most common primary intraocular malignancy in children, with 1 in 15,000 to 20,000 live births, resulting in about 8,000 new cases annually[ 2 ]. The disease arises from the inactivation of both RB1 alleles, leading to a defective retinoblastoma protein (pRb) that impairs cell cycle control and triggers unchecked cell proliferation. Autosomal dominant inheritance accounts for 30–40% of cases, usually in children at a younger age and accompanied by a high risk of bilateral secondary cancer, while the rest are sporadic and unilateral[ 3 ]. The RB1 gene spans 183 kilobases and encodes a 928 amino-acid phosphoprotein, whose function depends on phosphorylation. In a hypophosphorylated state, pRB binds to E2F transcription factors, halting the cell cycle at the G1 restriction point[ 4 ]. However, in retinoblastoma, pRb becomes non-functional due to mutations or deletions, leading to genomic instability and tumor formation[ 4 ]. NF is a multisystem tumor predisposition syndrome caused by genetic mutations, with NF1 resulting from a mutation on chromosome 17 (17q11.2) and NF2 from a mutation on chromosome 22 (22q12.2).[ 5 ] Although Riccardi originally proposed seven types of NF due to the disorder's clinical heterogeneity, more recent classifications recognize only NF1 and NF2, with the other types now considered variants[ 6 ]. NF1 also known as the von Recklinghausen disease is one of the most common hereditary diseases, with an estimated prevalence of 1/3000 ~ 3500[ 7 ]. A wide spectrum of ophthalmological manifestations characterizes the disease. NF2 is much less common than NF1, affecting about 1 in 25,000 people worldwide regardless of sex or ethnicity[ 8 ]. Mutations in the NF2 gene are highly associated with acoustic neuroma, a benign tumor that originates from vestibular Schwann cells[ 9 ]. This tumor commonly occurs in both ears, and bilateral acoustic neuroma is the signature feature of NF2. More than 90% of patients with NF2 develop this tumor early in life, typically before the average age of 30 years[ 9 ]. VHL disease is a rare autosomal dominantly inherited multisystem neoplastic condition caused by a mutation in the VHL gene. Key clinical features include hemangioblastomas of the brain and spinal cord, renal cell carcinoma (RCC), retinal hemangiomas (RH), pheochromocytoma, and cysts in the epididymis, pancreas, and kidneys[ 10 ]. The VHL tumor suppressor gene, responsible for the disease, encodes for a major regulator of the hypoxic response by targeting the transcription factor hypoxia-inducible factor (HIF) for degradation[ 11 ]. While most cases are hereditary, up to 20% arise from new mutations. The incidence is approximately 1 in 36,000 live births, with over 90% penetrance by age 65[ 12 ]. Despite advances in treatment, life expectancy remains 40–52 years, primarily due to metastatic RCC and central nervous system lesions[ 12 ]. TSC is an autosomal dominant disorder with near complete penetrance that results from mutations in TSCl or TSC2. TSCl is due to a heterozygous mutation of TSCl on chromosome 9q34, which encodes for the gene hamartin.[ 13 ] TSC2 is caused by a heterozygous mutation of TSC2, which encodes for the gene tuberin. Two-thirds of cases represent new events. TSC2 mutations (75–80%) are more common than TSC1 (10–30%).[ 13 ] Tuberin and hamartin are tumor suppressor genes that inhibit the mammalian target of the rapamycin (mTOR) pathway[ 14 ]. Loss of function of the tuberin or hamartin genes results in unregulated cell growth. TSC affects cell growth in different germ layers causing hamartomas in affected organ systems[ 15 ]. In retinal hamartomas, glial astrocytes and blood vessel growth are unregulated leading to characteristic retinal astrocytic hamartomas. Ocular manifestations are often among the earliest signs of these genetic syndromes, making ophthalmic examination crucial for early diagnosis. This study focuses on analyzing the ocular features of pediatric patients with RB1, NF1, NF2, VHL, and TSC mutations treated at our institution. By combining our findings with previous reports, we emphasize overlooked clinical features to improve early detection and management strategies. 2. PATIENTS AND METHODS This retrospective case series, combined with a systematic literature review, aimed to characterize the ocular manifestations of pediatric patients with confirmed mutations in tumor suppressor genes (RB1, NF1, NF2, VHL, TSC1/2). Between July 2022 and December 2024, 11 pediatric patients (< 18 years) were recruited from the Ophthalmology Department of the Affiliated Children's Hospital of Xiangya School of Medicine (Hunan Children’s Hospital). The inclusion criteria were: (1) genetically confirmed pathogenic variants in RB1, NF1, NF2, VHL, or TSC1/2 via clinical genetic testing; (2) comprehensive ophthalmic records available for analysis. Peripheral venous blood samples were collected from all participants, and genomic DNA was extracted using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. Whole-exome sequencing (WES) was performed on the Illumina NovaSeq 6000 platform (Illumina, San Diego, CA, USA). Variants were analyzed using the ANNOVAR pipeline and classified per ACMG/AMP guidelines, with Sanger sequencing confirming pathogenic/likely pathogenic variants. Table 1 Characteristics of Children with Gene Mutations in Tumor Suppressor Genes Gene Mutation Sex Age Variant Description Typical Ocular Manifestations RB1 Female Born in December 2023 c.1578delC (p.Arg527Glufs*66) Leukocoria, retinal tumor NF1 Female 2 years 11 months c.3113 + 1G > T (p.?) Lisch nodules, patchy pigmentation abnormalities, blurred optic disc, enlarged eyeball Female 4 years 8 months c.3381_3382del (p.Gly1128Trpfs*66) Female 5 years 7 months c.3525_3526del (p.Arg1176Serfs*18) Male 6 years 3 months c.5546G > A (p.Arg1849Gln) Male 5 years 3 months c.702_703del (p.Tyr235Profs*6) Male 1 year 9 months c.1882dupT (p.Tyr628Leufs*6) NF2 Female 11 years 8 months c.784C > T (p.Arg262Ter) Cataract, epiretinal membrane, macular edema VHL Female 14 years 2 months c.497C > T (p.Arg167Trp) retinal hemangioblastoma TSC1 Female 13 years 8 months c.733C > T (p.Arg245*) Thickening orbital nerves, pupil dilation, pale optic discs, and blurred disc margins, reitnal hamartoma TSC2 Male 5 years 10 months c.3696dupT (p.Asn1233*) Retinal hamartomas The study included 11 typical pediatric patients with confirmed genetic mutations, all diagnosed through WES and clinical genetic testing (Table 1 ). Each patient underwent detailed and comprehensive ophthalmologic evaluations. Depending on their cooperation and clinical necessity, they received slit-lamp examination, fundus examination, B-scan ultrasonography, spectral-domain optical coherence tomography (SD-OCT; Heidelberg Engineering, Heidelberg, Germany), fundus photography (TRC-50DX; Topcon, Tokyo, Japan) or ultra-widefield fundus photographs (Optos PLC; Dunfermline, Scotland, United Kingdom), orbital magnetic resonance imaging (MRI; 3.0T scanner, T1-weighted, T2-weighted, and contrast-enhanced imaging sequences Signa Premier, GE Healthcare, Chicago, IL, USA), best corrected visual acuity (BCVA) and other examinations to identify the ocular presentation. This study was approved by the Institutional Review Board of Hunan Children’s Hospital (No. HCHLL-2022-76) and conducted following the principles of the Declaration of Helsinki. Before the procedure, informed consent was obtained in writing from all participants' parents or legal guardians. In addition to the clinical cases, a systematic literature review was performed. We searched PubMed, Scopus, and Web of Science for articles published in the last 10 years focusing on the ocular manifestations of RB1, NF1, NF2, VHL, and TSC1/TSC2. Keywords included: "ocular manifestations," "RB1," "VHL," "NF1," "NF2," "TSC/TSC1/TSC2," "retinoblastoma," and "angiogenesis." Relevant articles were selected if they focused on pediatric patients with gene mutations associated with these syndromes. 3. RESULTS 3.1 Ocular Manifestations of RB1 Mutation in Retinoblastoma RB, resulting from RB1 gene inactivation, disrupts the normal regulation of retinal cell growth, leading to distinct ocular symptoms, particularly in children[ 16 ]. In our study, we introduced a patient, a girl with leukocoria born in December 2023 and diagnosed with Rb with autosomal dominant inheritance at 3 months, who had undergone multiple multidisciplinary treatments including intravenous chemotherapy (IVC) at a local hospital by April 2024. Upon her referral to our institution, her bilateral lesions were found to be relatively stable, and she received laser photocoagulation therapy for consolidation (Fig. 1 A, B). However, during a follow-up visit in August, new tumor (NT) development was noted in her right eye (Fig. 1 C, D), indicating the necessity for long-term regular follow-up and timely intervention. Leukocoria (abnormal white reflex) is the most common early symptom of RB, while delayed detection often worsens prognosis. Strabismus is frequently associated with macular tumors, and advanced cases may present with buphthalmos, neovascular glaucoma, or orbital inflammation. Tumor growth patterns include endophytic (into the vitreous), exophytic (with retinal detachment), and diffuse infiltrating (flat growth without a clear mass). Atypical variants, such as cavitary RB and retinocytoma, may also occur.[ 17 , 18 ] RB can manifest bilaterally, with trilateral forms involving intracranial tumors and rare quadrilateral forms including suprasellar tumors. Metastasis, though uncommon, may involve the optic nerve, choroid, or ciliary body.[ 3 , 18 ] Over the last three decades, IVC has played a major role in the conservative treatment of RB. The eventual globe salvage rate has usually been > 70% in several previous reports employing IVC and focal treatments [19] . However, long-term tumor control and the development of recurrence and NTs are still major concerns after IVC. High-risk factors for recurrence include age < 12 months at diagnosis, shorter tumor distance to the optic disc, higher International RB Classification, and subretinal seeds, while NT development is strongly associated with age < 6 months, familial RB, bilateral disease, and subretinal seeds[ 19 – 22 ]. Recurrence and NTs are treated with IVC, transpupillary thermotherapy, cryotherapy, plaque radiotherapy, external beam radiotherapy, and intra-arterial chemotherapy, either alone or in combination[ 17 , 23 ]. Advances in RB treatment have significantly reduced poor outcomes, such as vision loss and enucleation. Emerging strategies, including biomarker-based staging, targeted therapies, and extracellular vesicle analysis, offer promising prospects for early detection and improved outcomes, paving the way for precision medicine in RB care[ 24 ]. 3.2 Ocular Manifestations in NF1 and gene basis NF1 is caused by mutations in the NF1 tumor suppressor gene, which encodes neurofibromin, a protein that inhibits the RAS-MAPK pathway[ 7 ]. Disruption of this pathway promotes excessive cell growth and survival, leading to ocular neoplasms and other systemic manifestations. In this study, we analyzed six pediatric NF1 patients: three females aged 2 years 11 months, 4 years 8 months, and 5 years 7 months, and three males aged 6 years 3 months, 5 years 3 months, and 1 year 9 months. Many of these patients exhibited Lisch nodules, a hallmark of NF1, which appear on the surface of the iris (Fig. 2 A). However, one child did not present with Lisch nodules, but rather with focal, flattened patches of pigment on the iris (Fig. 2 B). Although these symptoms concerning the iris did not show clear ocular complaints, these benign iris hamartomas are a key diagnostic feature, easily detectable via slit-lamp examination[ 25 ]. In cases with orbital-facial involvement, associated ocular globe enlargement is often observed. Orbital MRI may demonstrate features such as enlarged eyeballs, abnormally thickened extraocular muscles, as shown in Fig. 2 D, bilateral optic nerve enlargement, thickening of the optic chiasm, and abnormal signal intensities in the brainstem and basal ganglia. These findings are highly suggestive of NF1 and align with observations reported in the existing literature[ 26 ]. OCT images revealed choroidal hyperreflectivity and blurred optic disc margins can be detected in some patients (Fig. 2 C, E). Systemically, nearly all presented with café-au-lait spots in the axillary, facial, or groin regions, further supporting the diagnosis of NF1[ 27 ]. Among our cases, a 1-year-9-month-old child presented with a white cornea resulting from increased intraocular pressure. Initially diagnosed with glaucoma at a local hospital, further investigation revealed a family history of glaucoma in both the mother and grandfather. Upon referral to our hospital, further diagnostic evaluation, including ocular B-scan ultrasonography, revealed an enlarged eyeball with an abnormally elongated axial length, thickened optic nerve, and a band-like high echo within the vitreous cavity (Fig. 2 F, G). Subsequent genetic testing confirmed the diagnosis of NF1. This case underscores diverse ocular clinical manifestations and initial symptoms of NF1 and highlights the critical importance of thorough clinical evaluation and genetic testing. Clinicians should adopt a meticulous approach, carefully investigating beyond initial findings to uncover deeper systemic or genetic abnormalities that may underlie the ocular symptoms. Additionally, multiple patients developed optic pathway gliomas, which are observed in approximately 15% of NF1 patients[ 26 ]. These gliomas sometimes led to strabismus and proptosis, necessitating neuroimaging and visual field testing for regular monitoring. Early intervention in symptomatic cases remains crucial to prevent visual loss.[ 27 ] Literature also suggests further ocular findings, including choroidal nodules and retinal vascular abnormalities, detectable using near-infrared reflectance imaging. OCT has provided detailed insights into retinal changes and assisted in managing optic gliomas, becoming essential for tracking ocular complications in pediatric NF1 patients.[ 28 , 29 ] Beyond ocular involvement, some patients in our cohort exhibited behavioral and cognitive deficits, common in NF1[ 7 ]. These systemic manifestations underscore multidisciplinary care's importance in effectively addressing ocular and non-ocular complications. Early diagnosis and comprehensive management are vital for optimizing outcomes in these patients. 3.3 Ocular Manifestations in NF2 and gene basis NF2 is caused by mutations in the NF2 gene on chromosome 22, which encodes Merlin, a protein that regulates cell proliferation and contact inhibition[ 30 ]. The disruption of this regulatory mechanism promotes uncontrolled cell growth and increases the likelihood of tumor formation. NF2 occurs in approximately 1 in 25,000 individuals worldwide, with about 50% of cases inherited through an autosomal dominant pattern, while the remaining cases arise from de novo mutations[ 31 ]. Although systemic manifestations such as bilateral vestibular schwannomas typically present in young adulthood, ocular symptoms often appear much earlier, particularly in pediatric patients, underscoring the importance of early screening.[ 31 ] Our cohort included an 11-year 8-month-old female patient who had experienced bilateral visual decline for over three years before hearing loss in both ears. Her family history revealed that her brother had been previously diagnosed with NF2 and had passed away three years after brain tumor surgery. The patient presented with multiple café-au-lait spots on her body and, during ophthalmologic evaluation, was found to have exotropia in the left eye, and mild cataracts in both eyes. And the epiretinal membrane (ERM) and macular edema as confirmed by OCT (Fig. 3 A). Her BCVA was 20/50 in both eyes, and no abnormalities were observed in the iris and other structures. These findings are consistent with prior studies, which report that ocular manifestations of NF2, can appear in childhood and precede the onset of more severe systemic symptoms[ 32 ]. Cataracts, observed in up to 80% of NF2 patients, may require surgical intervention to restore vision, especially as they progress. Retinal hamartomas and ERM, as identified in this patient, though less common, can significantly impair visual acuity and warrant continuous monitoring with OCT. The exotropia observed is aligned with previous reports of cranial nerve involvement in NF2, which may also lead to optic nerve sheath meningiomas or vestibular schwannomas affecting ocular motility. [ 8 , 31 ] Although ocular manifestations occur as the first sign in only 12% of NF2 cases, they often develop much earlier than systemic tumors, with some reports indicating onset as early as 5.6 years[ 5 , 32 ]. Therefore, regular ophthalmologic follow-ups are crucial in identifying these early changes, especially in children with a family history of NF2. Timely detection and intervention can help manage vision loss and provide better outcomes for these patients. 3.4 Ocular Manifestations in VHL and Gene Basis VHL disease is a rare, autosomal dominant hereditary syndrome caused by mutations in the VHL tumor suppressor gene, which encodes a protein regulating cellular responses to hypoxia and angiogenesis by targeting the transcription factor HIF for degradation[ 11 ]. Mutations in the VHL gene result in abnormal angiogenesis and the development of various tumors, with retinal hemangioblastomas being the most common ocular manifestations associated with the condition with a prevalence ranging from 30–58%[ 12 , 33 ]. In our study, we included a 14-year-old and 2-month-old female patient who had previously undergone adenoma resection for a hemangioblastoma at our institution. Following her surgery, she was advised to visit the ophthalmology department. Upon examination, a clear retinal lesion consistent with a retinal hemangioblastoma was identified in the superior nasal quadrant of her right eye (Fig. 3 B). Fortunately, her visual acuity remained stable, and there were no signs of inflammation, choroidal detachment, or other complications. Our department promptly performed laser photocoagulation treatment on her right eye, and she has shown stability in her condition during regular follow-up visits. In addition to retinal hemangioblastomas, patients with VHL may present with other ocular manifestations, such as retinal cysts and choroidal hemangiomas[ 10 ]. Retinal hemangioblastomas are often the earliest manifestation of VHL, potentially leading to vision loss through exudation, hemorrhage, or retinal detachment. Therefore, early detection via fundoscopy and subsequent treatment, including laser or cryotherapy, is crucial for preserving visual function and preventing complications. Given the potential ocular involvement in VHL, it is essential for patients diagnosed with this condition by other specialties to undergo routine ophthalmic evaluations. 3.5 Ocular Manifestations in TSC and Gene Basis TSC is a genetic disorder characterized by multi-system hamartomas resulting from mutations in the TSC1 and TSC2 genes, leading to the overactivation of the mTOR signaling pathway and dysregulation of cell proliferation[ 14 , 34 ]. Typically diagnosed in early childhood or adolescence, TSC is a chronic, multisystemic disorder with age-dependent manifestations that pose challenges for lifelong surveillance. In some studies, epilepsy remains one of the main neurological challenges, with over 90% of cases manifesting in childhood[ 13 ]. The abnormal performance of the eye requires vigilance in monitoring, paralleling the broader systemic challenges. Retinal hamartomas are the most common ocular feature in TSC, appearing as yellowish or calcified lesions. While typically asymptomatic, they may affect vision in rare cases, especially when lesions are located near the macula or optic disc. In our study, we included a 13-year-8-month-old female patient with a confirmed TSC1 mutation. She initially presented to the neurosurgery department with nausea and headache and was subsequently diagnosed with a subependymal giant cell astrocytoma with thickening bilateral orbital nerves, requiring neurosurgical intervention (Fig. 4 A, B). Since the onset of systemic symptoms, her vision has been severely impaired, and limited to light perception. Preoperative evaluation in our department revealed bilateral pupil dilation, pale optic discs, and blurred disc margins (Fig. 4 C-E). Postoperative examination showed no improvement in BCVA. While optic nerve edema had subsided, the optic discs remained pale (Fig. 4 F). OCT revealed the disorganization of outer photoreceptor segments in both eyes, with a suspected hamartoma in the right eye (Fig. 4 G-H). This case highlights the significant ocular complications associated with TSC1 mutations, particularly in the context of systemic manifestations and neurosurgical interventions. Additionally, we included a TSC2 patient, a 5-year and 10-month-old male, who presented with vision decline. Whole-exome sequencing confirmed a TSC2 mutation, and upon examination, bilateral retinal hamartomas were identified (Fig. 5 A-C). He underwent bilateral retinal laser photocoagulation, resulting in stable vision, with corrected visual acuity of 30/50 in the right eye and 20/50 in the left. Some TSC patients also exhibit choroidal depigmentation or other abnormalities, which can be observed during comprehensive ophthalmic exams[ 35 , 36 ]. The clinical significance of these findings remains under investigation. 3.6 Cross-Mechanisms in Tumor Suppressor Genes Affecting Ocular Manifestations Dysregulation of key signaling pathways, including E2F, Ras, mTOR, HIF-1α, and Hippo, was related to mutations in RB1, NF1, NF2, VHL, TSC1, and TSC2, contributing to abnormal cell growth, impaired apoptosis, disordered angiogenesis, and microenvironmental imbalances. Mutations in RB1, NF1, NF2, VHL, TSC1, and TSC2 play a significant role in these processes, and overlapping ocular manifestations may occur. The RB1 gene is involved in regulating the cell cycle, genomic stability, apoptosis, metabolism, and angiogenesis. Mutations in RB1 can activate the E2F pathway, driving the development of retinoblastoma, while its role in apoptosis is linked to the mTOR pathway[ 37 , 38 ]. Similarly, TSC1/TSC2 mutations upregulate mTOR signaling, causing hamartomas and disrupting cellular metabolism[ 34 ]. NF1 and NF2 mutations impact the Ras and Hippo pathways, respectively, leading to schwannomas and optic gliomas[ 5 ]. Notably, NF2 mutations also affect cell adhesion and cytoskeletal stability, thereby maintaining tissue integrity[ 9 , 30 ]. VHL gene mutations impair the regulation of HIF-1α, promoting abnormal angiogenesis and contributing to the formation of RH[ 11 ]. Furthermore, the mTOR and HIF-1α pathways intersect under hypoxic conditions, exacerbating oxidative stress and driving further pathological changes[ 39 ]. Both VHL and TSC1/TSC2 are crucial regulators of vascular homeostasis and metabolic responses, playing a central role in the tumor microenvironment[ 33 , 34 ]. The Ras-PI3K-AKT-mTOR and interaction between mTOR and HIF are particularly important in regulating cell growth and tissue metabolism, while pathways such as Ras, mTOR, HIF-1α, and Hippo also modulate the tumor microvascular environment[ 40 , 41 ]. Dysregulation of these interconnected signaling pathways not only underpins the development of systemic and ocular tumors but also contributes to progressive ocular damage and retinal pathologies. These processes highlight the complex interplay between tumor suppressor genes, their downstream pathways, and their roles in ocular disease manifestation. 4. Discussion The ocular manifestations of tumor suppressor gene mutations in pediatric patients, particularly those associated with RB1, NF1, NF2, VHL, and TSC, are critical for early diagnosis and management of systemic diseases. These findings often precede other clinical symptoms, underscoring the importance of comprehensive pediatric ophthalmologic examinations. In this study, we presented a case of bilateral retinoblastoma diagnosed at three months of age, which recurred in one eye following treatment. This case, along with previous literature, highlights several important points: 1. Children with retinoblastoma in both eyes are at a higher risk of relapse; 2. Smaller infants with retinoblastoma are more likely to experience recurrence; 3. Long-term follow-up is crucial for all retinoblastoma patients.[ 3 , 16 ] Interestingly, most cases in this study were not initially seen in the ophthalmology department; patients came to us for eye examinations after surgical or neurosurgical treatment. NF1 patients often exhibit distinctive ocular findings, such as Lisch nodules, which are pathognomonic and can be easily observed. These findings, along with the risk of optic pathway gliomas, underscore the need for routine ophthalmic evaluations. Our findings also highlight the importance of ongoing ocular assessments in TSC and VHL patients. For instance, retinal hemangioblastomas in VHL are often the first detectable signs and require early intervention to prevent complications like retinal detachment. Additionally, patients diagnosed with VHL in other specialties should receive regular eye evaluations. In TSC, retinal hamartomas serve as key diagnostic markers, reinforcing the need for routine eye examinations to facilitate early intervention for potential vision-threatening issues. This study has several limitations. First, the limited sample size (n = 11) may restrict the generalizability of findings, particularly for rare genotypes like NF2 and VHL. Second, incomplete long-term follow-up data preclude definitive conclusions on disease progression and treatment outcomes. Third, as a single-center study, results may not reflect regional variations in genetic epidemiology or healthcare practices. Future research should prioritize multicenter collaborations to expand sample size, and include comprehensive longitudinal outcomes. This study emphasizes the importance of tumor suppressor gene expression in ocular manifestations. Even when initial symptoms may not present in the eye, they serve as critical warning signs for other healthcare providers. As ophthalmologists, we must remain vigilant not only to ocular findings but also to the systemic manifestations associated with these gene abnormalities. A multidisciplinary approach involving pediatric ophthalmologists, geneticists, and other specialists is essential. Regular ophthalmic follow-ups are crucial for monitoring disease progression and adjusting treatment strategies. Ultimately, early diagnosis and continuous ophthalmic monitoring, combined with advancements in genetic research and personalized medicine, are vital for preserving vision and managing systemic complications in children with mutations in tumor suppressor genes. Functional studies exploring the mTOR-HIF-1α axis in VHL/TSC-related angiogenesis may uncover new therapeutic targets. We believe the integration of targeted therapies and personalized treatment protocols based on genetic profiles holds promise for improving patient outcomes and quality of life. 5. Conclusion Ocular manifestations serve as critical early indicators for hereditary cancer syndromes linked to RB1, NF1, NF2, VHL, and TSC mutations. Regular ophthalmic evaluations, and genetic testing combined with multidisciplinary care, are essential for timely diagnosis and improved outcomes. Larger sample sizes and long-term follow-up data are required to validate the generalizability of our findings and develop more comprehensive diagnostic and treatment protocols. Abbreviations RB1 retinoblastoma susceptibility gene NF1 neurofibromatosis type 1 VHL Von Hippel-Lindau TSC tuberous sclerosis complex RB retinoblastoma pRb retinoblastoma protein RCC renal cell carcinoma RH retinal hemangiomas HIF hypoxia-inducible factor mTOR mammalian target of the rapamycin WES whole-exome sequencing IVC intravenous chemotherapy NT new tumor OCT optical coherence tomography ERM epiretinal membrane Declarations Funding information: This work was supported by the Natural Science Foundation of Hunan Province of China to Yu Tian (2022JJ80005), the Hunan Disabled Rehabilitation Association Foundation of China to Yu Tian (2023XK0224), and the Changsha Science and Technology Project of China to Yu Tian (kh2401012). Funding information: This work was supported by the Natural Science Foundation of Hunan Province of China to Yu Tian (2022JJ80005), the Hunan Disabled Rehabilitation Association Foundation of China to Yu Tian (2023XK0224), and the Changsha Science and Technology Project of China to Yu Tian (kh2401012). Ethics approval and consent to participate This study was conducted following the principles of the Declaration of Helsinki. Informed consent was obtained in writing from the parents or legal guardians of all participants before the procedure. The Ethics Committee of Hunan Children’s Hospital granted ethical approval (No. HCHLL-2022-76). Clinical trial number: not applicable. Consent for Publication All co-authors have given their approval for the final manuscript and consented to its publication. Competing interests The authors declare no competing interests. CRediT authorship contribution statement Aoxiang Wang: Writing – original draft, Investigation, Visualization, Formal analysis. Chanyuan Wang: Writing – review & editing, Software, Methodology. Wen Li: Data curation. Jing Qiao: Conceptualizations. Yulin Luo: Writing – review & editing, Validation. Yu Tian: Writing – review & editing, Supervision, Funding acquisition, Conceptualization. References J. Zhang et al. , "Germline Mutations in Predisposition Genes in Pediatric Cancer," (in eng), N Engl J Med, vol. 373, no. 24, pp. 2336-2346, Dec 10 2015, doi: 10.1056/NEJMoa1508054. H. Dimaras et al. , "Retinoblastoma," (in eng), Nat Rev Dis Primers, vol. 1, p. 15021, Aug 27 2015, doi: 10.1038/nrdp.2015.21. C. C. Cruz-Gálvez, J. C. Ordaz-Favila, V. M. Villar-Calvo, M. E. Cancino-Marentes, and V. Bosch-Canto, "Retinoblastoma: Review and new insights," (in eng), Front Oncol, vol. 12, p. 963780, 2022, doi: 10.3389/fonc.2022.963780. Y. Yao, X. Gu, X. Xu, S. Ge, and R. Jia, "Novel insights into RB1 mutation," (in eng), Cancer Lett, vol. 547, p. 215870, Oct 28 2022, doi: 10.1016/j.canlet.2022.215870. T. Mühlenberg et al. , "KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy," (in eng), Mol Cancer Ther, vol. 18, no. 11, pp. 1985-1996, Nov 2019, doi: 10.1158/1535-7163.Mct-18-1224. E. Uusitalo et al. , "Incidence and Mortality of Neurofibromatosis: A Total Population Study in Finland," Journal of Investigative Dermatology, vol. 135, no. 3, pp. 904-906, 2015/3/1, doi: 10.1038/jid.2014.465. M. Nebbioso et al. , "Neurofibromatosis Type 1: Ocular Electrophysiological and Perimetric Anomalies," (in eng), Eye Brain, vol. 12, pp. 119-127, 2020, doi: 10.2147/eb.S255184. A. Romero-Titos, P. Álvarez-Sánchez, F. M. H. Fernández, M. Castro-Gómez, and B. B. Blasco, "Retinal astrocytic hamartoma: A rare ocular presentation in neurofibromatosis type 2," (in eng), J Fr Ophtalmol, vol. 46, no. 9, pp. e317-e320, Nov 2023, doi: 10.1016/j.jfo.2023.03.013. D. A. Hilton and C. O. Hanemann, "Schwannomas and their pathogenesis," (in eng), Brain Pathol, vol. 24, no. 3, pp. 205-20, Apr 2014, doi: 10.1111/bpa.12125. A. B. Daniels et al. , "Guidelines for surveillance of patients with von Hippel-Lindau disease: Consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance," (in eng), Cancer, vol. 129, no. 19, pp. 2927-2940, Oct 1 2023, doi: 10.1002/cncr.34896. S. Mazumder, P. J. Higgins, and R. Samarakoon, "Downstream Targets of VHL/HIF-α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance," (in eng), Cancers (Basel), vol. 15, no. 4, Feb 19 2023, doi: 10.3390/cancers15041316. S. Karimi, A. Arabi, T. Shahraki, and S. Safi, "Von Hippel-Lindau Disease and the Eye," (in eng), J Ophthalmic Vis Res, vol. 15, no. 1, pp. 78-94, Jan-Mar 2020, doi: 10.18502/jovr.v15i1.5950. K. A. Orlova and P. B. Crino, "The tuberous sclerosis complex," (in eng), Ann N Y Acad Sci, vol. 1184, pp. 87-105, Jan 2010, doi: 10.1111/j.1749-6632.2009.05117.x. H. C. Lam et al. , "p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis," (in eng), Cancer Res, vol. 77, no. 12, pp. 3255-3267, Jun 15 2017, doi: 10.1158/0008-5472.Can-16-2458. P. B. Dias et al. , "Optical coherence tomography detection of retinal neural loss in patients with tuberous sclerosis," (in eng), Int J Retina Vitreous, vol. 10, no. 1, p. 15, Feb 4 2024, doi: 10.1186/s40942-024-00535-7. L. Singh et al. , "Epidemiology, Diagnosis and Genetics of Retinoblastoma: ICMR Consensus Guidelines," (in eng), Indian J Pediatr, vol. 91, no. 11, pp. 1147-1156, Nov 2024, doi: 10.1007/s12098-024-05085-2. R. Kaewkhaw and D. Rojanaporn, "Retinoblastoma: Etiology, Modeling, and Treatment," (in eng), Cancers (Basel), vol. 12, no. 8, Aug 16 2020, doi: 10.3390/cancers12082304. O. Warda, Z. Naeem, K. A. Roelofs, M. S. Sagoo, and M. A. Reddy, "Retinoblastoma and vision," (in eng), Eye (Lond), vol. 37, no. 5, pp. 797-808, Apr 2023, doi: 10.1038/s41433-021-01845-y. A. K. Gündüz, I. Mirzayev, H. Dinçaslan, and F. S. Özalp Ateş, "Recurrence and new tumor development after frontline intravenous chemotherapy for retinoblastoma: Risk factors and treatment results," (in eng), Eur J Ophthalmol, vol. 32, no. 3, pp. 1795-1803, May 2022, doi: 10.1177/11206721211023311. T. C. Lee, N. I. Hayashi, I. J. Dunkel, K. Beaverson, D. Novetsky, and D. H. Abramson, "New retinoblastoma tumor formation in children initially treated with systemic carboplatin," (in eng), Ophthalmology, vol. 110, no. 10, pp. 1989-94; discussion 1994-5, Oct 2003, doi: 10.1016/s0161-6420(03)00669-9. J. Li et al. , "Outcome of salvage intra-arterial chemotherapy for recurrent retinoblastoma," (in eng), Eye (Lond), vol. 36, no. 11, pp. 2106-2110, Nov 2022, doi: 10.1038/s41433-021-01693-w. S. Kaliki, V. S. Vempuluru, Y. Priya, and A. Mohamed, "Risk factors for recurrent retinoblastoma after intravenous chemotherapy," (in eng), Int Ophthalmol, vol. 41, no. 6, pp. 2033-2039, Jun 2021, doi: 10.1007/s10792-021-01759-4. Z. X. Feng, J. Zhao, N. Zhang, M. Jin, and B. Gallie, "Adjuvant Chemotherapy Improves Survival for Children With Massive Choroidal Invasion of Retinoblastoma," (in eng), Invest Ophthalmol Vis Sci, vol. 64, no. 11, p. 27, Aug 1 2023, doi: 10.1167/iovs.64.11.27. R. Manukonda, R. V. Narayana, S. Kaliki, D. K. Mishra, and G. K. Vemuganti, "Emerging therapeutic targets for retinoblastoma," (in eng), Expert Opin Ther Targets, vol. 26, no. 11, pp. 937-947, Nov 2022, doi: 10.1080/14728222.2022.2158812. V. M. Riccardi, "Neurofibromatosis: past, present, and future," (in eng), N Engl J Med, vol. 324, no. 18, pp. 1283-5, May 2 1991, doi: 10.1056/nejm199105023241812. K. I. Ly and J. O. Blakeley, "The Diagnosis and Management of Neurofibromatosis Type 1," (in eng), Med Clin North Am, vol. 103, no. 6, pp. 1035-1054, Nov 2019, doi: 10.1016/j.mcna.2019.07.004. D. T. Miller, D. Freedenberg, E. Schorry, N. J. Ullrich, D. Viskochil, and B. R. Korf, "Health Supervision for Children With Neurofibromatosis Type 1," (in eng), Pediatrics, vol. 143, no. 5, May 2019, doi: 10.1542/peds.2019-0660. B. Abdolrahimzadeh, D. C. Piraino, G. Albanese, F. Cruciani, and S. Rahimi, "Neurofibromatosis: an update of ophthalmic characteristics and applications of optical coherence tomography," (in eng), Clin Ophthalmol, vol. 10, pp. 851-60, 2016, doi: 10.2147/opth.S102830. S. Abdolrahimzadeh, M. Formisano, F. Guglielmelli, S. Amodeo, M. C. Costa, and G. Scuderi, "Unusual Case of Indolent Choroidal Alterations Mimicking Neurofibromatosis Type 1," (in eng), Case Rep Ophthalmol, vol. 11, no. 2, pp. 167-173, May-Aug 2020, doi: 10.1159/000507428. K. H. Moon et al. , "Differential Expression of NF2 in Neuroepithelial Compartments Is Necessary for Mammalian Eye Development," (in eng), Dev Cell, vol. 44, no. 1, pp. 13-28.e3, Jan 8 2018, doi: 10.1016/j.devcel.2017.11.011. A. Plana-Pla, I. Bielsa-Marsol, and C. Carrato-Moñino, "Diagnostic and Prognostic Relevance of the Cutaneous Manifestations of Neurofibromatosis Type 2," (in eng spa), Actas Dermosifiliogr, vol. 108, no. 7, pp. 630-636, Sep 2017, doi: 10.1016/j.ad.2016.12.007. Manifestaciones cutáneas de la neurofibromatosis tipo 2: interés diagnóstico y pronóstico. R. Tamura, "Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis," (in eng), Int J Mol Sci, vol. 22, no. 11, May 29 2021, doi: 10.3390/ijms22115850. D. Zhao et al. , "iASPP is essential for HIF-1α stabilization to promote angiogenesis and glycolysis via attenuating VHL-mediated protein degradation," (in eng), Oncogene, vol. 41, no. 13, pp. 1944-1958, Mar 2022, doi: 10.1038/s41388-022-02234-9. O. Vorobichik Berar et al. , "Mammalian target of rapamycin inhibitors for the treatment of astrocytic hamartoma in tuberous sclerosis complex (TSC)," (in eng), Graefes Arch Clin Exp Ophthalmol, vol. 260, no. 9, pp. 3061-3068, Sep 2022, doi: 10.1007/s00417-022-05585-x. L. Licchetta et al. , "Tuberous sclerosis complex in adulthood: focus on epilepsy prognosis," (in eng), Epilepsy Behav, vol. 153, p. 109688, Apr 2024, doi: 10.1016/j.yebeh.2024.109688. G. M. Bacci, S. Polizzi, F. Mari, V. Conti, R. Caputo, and R. Guerrini, "Atypical Ocular Coloboma in Tuberous Sclerosis-2: Report of Two Novel Cases," (in eng), J Neuroophthalmol, vol. 41, no. 3, pp. e363-e365, Sep 1 2021, doi: 10.1097/wno.0000000000001099. J. L. Berry, A. Polski, W. K. Cavenee, T. P. Dryja, A. L. Murphree, and B. L. Gallie, "The RB1 Story: Characterization and Cloning of the First Tumor Suppressor Gene," (in eng), Genes (Basel), vol. 10, no. 11, Nov 1 2019, doi: 10.3390/genes10110879. E. Le Rhun et al. , "Molecular targeted therapy of glioblastoma," (in eng), Cancer Treat Rev, vol. 80, p. 101896, Nov 2019, doi: 10.1016/j.ctrv.2019.101896. S. H. Baik et al. , "A Breakdown in Metabolic Reprogramming Causes Microglia Dysfunction in Alzheimer's Disease," (in eng), Cell Metab, vol. 30, no. 3, pp. 493-507.e6, Sep 3 2019, doi: 10.1016/j.cmet.2019.06.005. H. Jiang, A. M. Li, and J. Ye, "The magic bullet: Niclosamide," (in eng), Front Oncol, vol. 12, p. 1004978, 2022, doi: 10.3389/fonc.2022.1004978. S. Chakraborty, M. Balan, A. Sabarwal, T. K. Choueiri, and S. Pal, "Metabolic reprogramming in renal cancer: Events of a metabolic disease," (in eng), Biochim Biophys Acta Rev Cancer, vol. 1876, no. 1, p. 188559, Aug 2021, doi: 10.1016/j.bbcan.2021.188559. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Published Journal Publication published 10 May, 2025 Read the published version in BMC Pediatrics → Version 1 posted Editorial decision: Revision requested 03 Apr, 2025 Reviews received at journal 31 Mar, 2025 Reviewers agreed at journal 28 Mar, 2025 Reviewers invited by journal 28 Mar, 2025 Submission checks completed at journal 26 Mar, 2025 First submitted to journal 26 Mar, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-5838014","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":435886082,"identity":"0a1f064f-468f-46a2-a367-2664385d9c75","order_by":0,"name":"Aoxiang Wang","email":"","orcid":"","institution":"Central South University (Hunan Children’s Hospital)","correspondingAuthor":false,"prefix":"","firstName":"Aoxiang","middleName":"","lastName":"Wang","suffix":""},{"id":435886083,"identity":"13165322-a237-4c34-bcbf-c9192919b5cb","order_by":1,"name":"Chanyuan Wang","email":"","orcid":"","institution":"Central South University (Hunan Children’s Hospital)","correspondingAuthor":false,"prefix":"","firstName":"Chanyuan","middleName":"","lastName":"Wang","suffix":""},{"id":435886084,"identity":"33212bed-2490-4c9e-af22-a55723f195a2","order_by":2,"name":"Wen Li","email":"","orcid":"","institution":"Central South University (Hunan Children’s Hospital)","correspondingAuthor":false,"prefix":"","firstName":"Wen","middleName":"","lastName":"Li","suffix":""},{"id":435886085,"identity":"e825679a-efc1-4c54-b1be-41f672091e8a","order_by":3,"name":"Jing Qiao","email":"","orcid":"","institution":"Central South University (Hunan Children’s Hospital)","correspondingAuthor":false,"prefix":"","firstName":"Jing","middleName":"","lastName":"Qiao","suffix":""},{"id":435886086,"identity":"0b9b1eec-5d6a-424a-8ac6-a4693191b57a","order_by":4,"name":"Yulin Luo","email":"","orcid":"","institution":"Central South University (Hunan Children’s Hospital)","correspondingAuthor":false,"prefix":"","firstName":"Yulin","middleName":"","lastName":"Luo","suffix":""},{"id":435886087,"identity":"6a162399-a21e-44c9-8c60-4ade0d06eb6b","order_by":5,"name":"Yu Tian","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABD0lEQVRIiWNgGAWjYDACZjBZUz+f4fjxDx8qIIIS+HTwQLQcY9zYeCaNccYZYrRA7WJsOHzAjJm3jQgt9uzMzx7ztrExM7YdSHs4c56dvcEB5oO3eRjs8nA7jM3cmLdNho2d5+Bxg4/bkhM3HGBLtuZhSC7G4xczaaAtPIwzDiRIztx2IMHgAI+ZNA/DgcQGnFrYvwG1MEsw3H9gIM075wDQYfzfCGjhAdnCbMBw4ACQ0XCAccMBHjb8Wg7zlEnOOXcswbDhTLLhjGPJiTMPsxlbzjFIxqmFvf/4Nok3ZTUJ8gzHDz74UGNnz3e8+eGNNxV2OLWAABMPChccuQZ41AMB4w/88qNgFIyCUTDSAQCtTFSyRam/PQAAAABJRU5ErkJggg==","orcid":"","institution":"Central South University (Hunan Children’s Hospital)","correspondingAuthor":true,"prefix":"","firstName":"Yu","middleName":"","lastName":"Tian","suffix":""}],"badges":[],"createdAt":"2025-01-16 02:38:10","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-5838014/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-5838014/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1186/s12887-025-05694-6","type":"published","date":"2025-05-10T15:57:49+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":79582862,"identity":"0cafd760-1eea-44a0-85a5-5d83e0d075b9","added_by":"auto","created_at":"2025-03-31 12:08:45","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":1345022,"visible":true,"origin":"","legend":"\u003cp\u003eOcular manifestations caused by RB1 gene mutation\u003c/p\u003e\n\u003cp\u003e(A) Initial diagnosis of a stable tumor in a child with RB. (B) B-scan ultrasonography shows a high-density shadow adjacent to the posterior wall of the eyeball. (C) Four months later, a new tumor pattern appeared in the infratemporal portion of the primary lesion (red arrow). (D) OCT shows the retinal interlayer status corresponding to C's new tumor mass, with unclear boundaries and medium-low reflectivity.\u003c/p\u003e","description":"","filename":"figure1RB1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-5838014/v1/50c04ff1c9b2ea0ab5314640.jpg"},{"id":79582855,"identity":"69b59172-7cc6-4212-a862-90d32156069c","added_by":"auto","created_at":"2025-03-31 12:08:44","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":2727702,"visible":true,"origin":"","legend":"\u003cp\u003eOcular clinical manifestations caused by NF1 gene mutation\u003c/p\u003e\n\u003cp\u003e(A) The characteristic clinical manifestations of NF1 include Lisch nodules, appearing as protrusions on the iris surface with a scattered distribution (black arrows). (B) Patchy pigmentation abnormalities in the lower iris represent another iris-related feature associated with NF1. (C) OCT imaging demonstrates hyperreflective dots in the choroid (yellow arrow). (D) Orbital MRI in the T2 phase shows different degrees of abnormal thickening of the bilateral optic nerves and optic chiasma, with the right side heavier than the left side (red arrow) and abnormal signals near the brainstem (white arrow). (E) Fundus examination in this child with NF1 reveals a blurred optic disc. (F, G) Ocular B-scan ultrasonography identifies vitreous opacities, band-like echoes in the vitreous cavity, and optic nerve thickening (white circle).\u003c/p\u003e","description":"","filename":"figure2NF1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-5838014/v1/6e07e9ccc3434689f3d5a58f.jpg"},{"id":79584245,"identity":"21809dcd-37cc-4d8d-91d7-deefcf399d68","added_by":"auto","created_at":"2025-03-31 12:16:44","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":1418656,"visible":true,"origin":"","legend":"\u003cp\u003eOcular clinical manifestations caused by NF2 and VHL gene mutation\u003c/p\u003e\n\u003cp\u003e(A) A child with an NF2 gene mutation presenting with macular epiretinal membrane. OCT demonstrates disruption of the macular foveal contour and macular edema with a central retinal thickness of 550μm. (B) Fundus photograph of a child with a VHL gene mutation showing a retinal hemangioma located superior to the nasal aspect of the optic disc.\u003c/p\u003e","description":"","filename":"figure3NF2VHL.jpg","url":"https://assets-eu.researchsquare.com/files/rs-5838014/v1/5e86d9d16bbcfefff9f7a9b1.jpg"},{"id":79582926,"identity":"db9f0ec9-c2a8-4261-bac8-a2976182ba3d","added_by":"auto","created_at":"2025-03-31 12:08:46","extension":"jpg","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":3475206,"visible":true,"origin":"","legend":"\u003cp\u003eOcular clinical manifestations caused by TSC1 gene mutation\u003c/p\u003e\n\u003cp\u003e(A, B) The MRI scan during the T2 phase showed thickening bilateral optic nerves (black arrows) and high signal intensity in the ependyma (red arrow). (C, D) The pupil of the child with TSC1 gene mutation was dilated and fixed without light reflection. (E) Fundus photography revealed pale optic discs with blurred edges in the right eye before the neurosurgery operation. (F) Postoperative fundus images showed that the patient's optic disc edema improved, but the color of the optic disc was still pale. (G, H) OCT showed structural disorganization in the outer photoreceptor segment in both eyes. In G, foveal deformation and suspected hamartoma can be detected (yellow arrow).\u003c/p\u003e","description":"","filename":"figure4TSC1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-5838014/v1/8b23770d92602c4407bb783a.jpg"},{"id":79585412,"identity":"3c529937-ddfb-4aea-8265-b69927cb0fe8","added_by":"auto","created_at":"2025-03-31 12:24:47","extension":"jpg","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":2495350,"visible":true,"origin":"","legend":"\u003cp\u003eOcular clinical manifestations caused by TSC2 gene mutation\u003c/p\u003e\n\u003cp\u003e(A, B) Retinal hamartomas were identified in the optic disc and macular regions, with evidence of retinal structural disorganization. Retinal cavities were observed within the internal layers of the tumors, along with irregular and abnormally high spot-like reflections between retinal layers in other areas. (C) Fundus photography revealed multiple retinal hamartomas as circular protrusions in various locations of the retina.\u003c/p\u003e","description":"","filename":"figure5TSC2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-5838014/v1/e10afd11d501957282a7fbe9.jpg"},{"id":82537643,"identity":"e659c0c2-92b5-479d-a9df-8607ada0d11e","added_by":"auto","created_at":"2025-05-12 16:09:42","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":12247478,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-5838014/v1/017a38a1-06f8-493a-ae96-38518b66a80a.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Ocular Manifestations in Pediatric Tumor Suppressor Gene Mutations: A Case Series and Literature Review of RB1, NF1, NF2, VHL, and TSC","fulltext":[{"header":"1. INTRODUCTION","content":"\u003cp\u003ePediatric patients with mutations in tumor suppressor genes, including the retinoblastoma susceptibility gene (RB1), neurofibromatosis type 1 (NF1), NF2, Von Hippel-Lindau (VHL), and tuberous sclerosis complex (TSC), often exhibit distinct or indistinct ocular manifestations that are essential for early diagnosis. These mutations predispose children to both ocular and systemic tumors, leading to complications that can severely affect vision and quality of life. The eye space caused by the mutation of these tumor suppressor genes has accounted for the majority of space-occupying diseases in children's ophthalmology. Understanding the unique ocular manifestations in children provides critical insights for early diagnosis and potential systemic screening. Regular ophthalmic evaluations in genetically predisposed children can facilitate early detection of eye-related abnormalities, ensuring timely intervention before visual and systemic complications arise.[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]\u003c/p\u003e \u003cp\u003eRetinoblastoma (RB) is the most common primary intraocular malignancy in children, with 1 in 15,000 to 20,000 live births, resulting in about 8,000 new cases annually[\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. The disease arises from the inactivation of both RB1 alleles, leading to a defective retinoblastoma protein (pRb) that impairs cell cycle control and triggers unchecked cell proliferation. Autosomal dominant inheritance accounts for 30\u0026ndash;40% of cases, usually in children at a younger age and accompanied by a high risk of bilateral secondary cancer, while the rest are sporadic and unilateral[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. The RB1 gene spans 183 kilobases and encodes a 928 amino-acid phosphoprotein, whose function depends on phosphorylation. In a hypophosphorylated state, pRB binds to E2F transcription factors, halting the cell cycle at the G1 restriction point[\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. However, in retinoblastoma, pRb becomes non-functional due to mutations or deletions, leading to genomic instability and tumor formation[\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eNF is a multisystem tumor predisposition syndrome caused by genetic mutations, with NF1 resulting from a mutation on chromosome 17 (17q11.2) and NF2 from a mutation on chromosome 22 (22q12.2).[\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e] Although Riccardi originally proposed seven types of NF due to the disorder's clinical heterogeneity, more recent classifications recognize only NF1 and NF2, with the other types now considered variants[\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. NF1 also known as the von Recklinghausen disease is one of the most common hereditary diseases, with an estimated prevalence of 1/3000\u0026thinsp;~\u0026thinsp;3500[\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. A wide spectrum of ophthalmological manifestations characterizes the disease. NF2 is much less common than NF1, affecting about 1 in 25,000 people worldwide regardless of sex or ethnicity[\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. Mutations in the NF2 gene are highly associated with acoustic neuroma, a benign tumor that originates from vestibular Schwann cells[\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. This tumor commonly occurs in both ears, and bilateral acoustic neuroma is the signature feature of NF2. More than 90% of patients with NF2 develop this tumor early in life, typically before the average age of 30 years[\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eVHL disease is a rare autosomal dominantly inherited multisystem neoplastic condition caused by a mutation in the VHL gene. Key clinical features include hemangioblastomas of the brain and spinal cord, renal cell carcinoma (RCC), retinal hemangiomas (RH), pheochromocytoma, and cysts in the epididymis, pancreas, and kidneys[\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. The VHL tumor suppressor gene, responsible for the disease, encodes for a major regulator of the hypoxic response by targeting the transcription factor hypoxia-inducible factor (HIF) for degradation[\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. While most cases are hereditary, up to 20% arise from new mutations. The incidence is approximately 1 in 36,000 live births, with over 90% penetrance by age 65[\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. Despite advances in treatment, life expectancy remains 40\u0026ndash;52 years, primarily due to metastatic RCC and central nervous system lesions[\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eTSC is an autosomal dominant disorder with near complete penetrance that results from mutations in TSCl or TSC2. TSCl is due to a heterozygous mutation of TSCl on chromosome 9q34, which encodes for the gene hamartin.[\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e] TSC2 is caused by a heterozygous mutation of TSC2, which encodes for the gene tuberin. Two-thirds of cases represent new events. TSC2 mutations (75\u0026ndash;80%) are more common than TSC1 (10\u0026ndash;30%).[\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e] Tuberin and hamartin are tumor suppressor genes that inhibit the mammalian target of the rapamycin (mTOR) pathway[\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. Loss of function of the tuberin or hamartin genes results in unregulated cell growth. TSC affects cell growth in different germ layers causing hamartomas in affected organ systems[\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. In retinal hamartomas, glial astrocytes and blood vessel growth are unregulated leading to characteristic retinal astrocytic hamartomas.\u003c/p\u003e \u003cp\u003eOcular manifestations are often among the earliest signs of these genetic syndromes, making ophthalmic examination crucial for early diagnosis. This study focuses on analyzing the ocular features of pediatric patients with RB1, NF1, NF2, VHL, and TSC mutations treated at our institution. By combining our findings with previous reports, we emphasize overlooked clinical features to improve early detection and management strategies.\u003c/p\u003e"},{"header":"2. PATIENTS AND METHODS","content":"\u003cp\u003eThis retrospective case series, combined with a systematic literature review, aimed to characterize the ocular manifestations of pediatric patients with confirmed mutations in tumor suppressor genes (RB1, NF1, NF2, VHL, TSC1/2). Between July 2022 and December 2024, 11 pediatric patients (\u0026lt;\u0026thinsp;18 years) were recruited from the Ophthalmology Department of the Affiliated Children's Hospital of Xiangya School of Medicine (Hunan Children\u0026rsquo;s Hospital). The inclusion criteria were: (1) genetically confirmed pathogenic variants in RB1, NF1, NF2, VHL, or TSC1/2 via clinical genetic testing; (2) comprehensive ophthalmic records available for analysis.\u003c/p\u003e \u003cp\u003ePeripheral venous blood samples were collected from all participants, and genomic DNA was extracted using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer\u0026rsquo;s protocol. Whole-exome sequencing (WES) was performed on the Illumina NovaSeq 6000 platform (Illumina, San Diego, CA, USA). Variants were analyzed using the ANNOVAR pipeline and classified per ACMG/AMP guidelines, with Sanger sequencing confirming pathogenic/likely pathogenic variants.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eCharacteristics of Children with Gene Mutations in Tumor Suppressor Genes\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGene Mutation\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSex\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eAge\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eVariant Description\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eTypical Ocular Manifestations\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRB1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eBorn in December 2023\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ec.1578delC (p.Arg527Glufs*66)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eLeukocoria, retinal tumor\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNF1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2 years 11 months\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ec.3113\u0026thinsp;+\u0026thinsp;1G\u0026thinsp;\u0026gt;\u0026thinsp;T (p.?)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"5\" rowspan=\"6\"\u003e \u003cp\u003eLisch nodules, patchy pigmentation abnormalities, blurred optic disc, enlarged eyeball\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4 years 8 months\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ec.3381_3382del (p.Gly1128Trpfs*66)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5 years 7 months\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ec.3525_3526del (p.Arg1176Serfs*18)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6 years 3 months\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ec.5546G\u0026thinsp;\u0026gt;\u0026thinsp;A (p.Arg1849Gln)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5 years 3 months\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ec.702_703del (p.Tyr235Profs*6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 year 9 months\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ec.1882dupT (p.Tyr628Leufs*6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNF2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e11 years 8 months\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ec.784C\u0026thinsp;\u0026gt;\u0026thinsp;T (p.Arg262Ter)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eCataract, epiretinal membrane, macular edema\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eVHL\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e14 years 2 months\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ec.497C\u0026thinsp;\u0026gt;\u0026thinsp;T (p.Arg167Trp)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eretinal hemangioblastoma\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTSC1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e13 years 8 months\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ec.733C\u0026thinsp;\u0026gt;\u0026thinsp;T (p.Arg245*)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eThickening orbital nerves, pupil dilation, pale optic discs, and blurred disc margins, reitnal hamartoma\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTSC2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5 years 10 months\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ec.3696dupT (p.Asn1233*)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eRetinal hamartomas\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eThe study included 11 typical pediatric patients with confirmed genetic mutations, all diagnosed through WES and clinical genetic testing (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). Each patient underwent detailed and comprehensive ophthalmologic evaluations. Depending on their cooperation and clinical necessity, they received slit-lamp examination, fundus examination, B-scan ultrasonography, spectral-domain optical coherence tomography (SD-OCT; Heidelberg Engineering, Heidelberg, Germany), fundus photography (TRC-50DX; Topcon, Tokyo, Japan) or ultra-widefield fundus photographs (Optos PLC; Dunfermline, Scotland, United Kingdom), orbital magnetic resonance imaging (MRI; 3.0T scanner, T1-weighted, T2-weighted, and contrast-enhanced imaging sequences Signa Premier, GE Healthcare, Chicago, IL, USA), best corrected visual acuity (BCVA) and other examinations to identify the ocular presentation.\u003c/p\u003e \u003cp\u003eThis study was approved by the Institutional Review Board of Hunan Children\u0026rsquo;s Hospital (No. HCHLL-2022-76) and conducted following the principles of the Declaration of Helsinki. Before the procedure, informed consent was obtained in writing from all participants' parents or legal guardians.\u003c/p\u003e \u003cp\u003eIn addition to the clinical cases, a systematic literature review was performed. We searched PubMed, Scopus, and Web of Science for articles published in the last 10 years focusing on the ocular manifestations of RB1, NF1, NF2, VHL, and TSC1/TSC2. Keywords included: \"ocular manifestations,\" \"RB1,\" \"VHL,\" \"NF1,\" \"NF2,\" \"TSC/TSC1/TSC2,\" \"retinoblastoma,\" and \"angiogenesis.\" Relevant articles were selected if they focused on pediatric patients with gene mutations associated with these syndromes.\u003c/p\u003e"},{"header":"3. RESULTS","content":"\u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003e3.1 Ocular Manifestations of RB1 Mutation in Retinoblastoma\u003c/h2\u003e \u003cp\u003eRB, resulting from RB1 gene inactivation, disrupts the normal regulation of retinal cell growth, leading to distinct ocular symptoms, particularly in children[\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. In our study, we introduced a patient, a girl with leukocoria born in December 2023 and diagnosed with Rb with autosomal dominant inheritance at 3 months, who had undergone multiple multidisciplinary treatments including intravenous chemotherapy (IVC) at a local hospital by April 2024. Upon her referral to our institution, her bilateral lesions were found to be relatively stable, and she received laser photocoagulation therapy for consolidation (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e1\u003c/span\u003eA, B). However, during a follow-up visit in August, new tumor (NT) development was noted in her right eye (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e1\u003c/span\u003eC, D), indicating the necessity for long-term regular follow-up and timely intervention.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eLeukocoria (abnormal white reflex) is the most common early symptom of RB, while delayed detection often worsens prognosis. Strabismus is frequently associated with macular tumors, and advanced cases may present with buphthalmos, neovascular glaucoma, or orbital inflammation. Tumor growth patterns include endophytic (into the vitreous), exophytic (with retinal detachment), and diffuse infiltrating (flat growth without a clear mass). Atypical variants, such as cavitary RB and retinocytoma, may also occur.[\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e] RB can manifest bilaterally, with trilateral forms involving intracranial tumors and rare quadrilateral forms including suprasellar tumors. Metastasis, though uncommon, may involve the optic nerve, choroid, or ciliary body.[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]\u003c/p\u003e \u003cp\u003eOver the last three decades, IVC has played a major role in the conservative treatment of RB. The eventual globe salvage rate has usually been \u0026gt;\u0026thinsp;70% in several previous reports employing IVC and focal treatments\u003csup\u003e[19]\u003c/sup\u003e. However, long-term tumor control and the development of recurrence and NTs are still major concerns after IVC. High-risk factors for recurrence include age\u0026thinsp;\u0026lt;\u0026thinsp;12 months at diagnosis, shorter tumor distance to the optic disc, higher International RB Classification, and subretinal seeds, while NT development is strongly associated with age\u0026thinsp;\u0026lt;\u0026thinsp;6 months, familial RB, bilateral disease, and subretinal seeds[\u003cspan additionalcitationids=\"CR20 CR21\" citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. Recurrence and NTs are treated with IVC, transpupillary thermotherapy, cryotherapy, plaque radiotherapy, external beam radiotherapy, and intra-arterial chemotherapy, either alone or in combination[\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]. Advances in RB treatment have significantly reduced poor outcomes, such as vision loss and enucleation. Emerging strategies, including biomarker-based staging, targeted therapies, and extracellular vesicle analysis, offer promising prospects for early detection and improved outcomes, paving the way for precision medicine in RB care[\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e].\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003e3.2 Ocular Manifestations in NF1 and gene basis\u003c/h2\u003e \u003cp\u003eNF1 is caused by mutations in the NF1 tumor suppressor gene, which encodes neurofibromin, a protein that inhibits the RAS-MAPK pathway[\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. Disruption of this pathway promotes excessive cell growth and survival, leading to ocular neoplasms and other systemic manifestations.\u003c/p\u003e \u003cp\u003eIn this study, we analyzed six pediatric NF1 patients: three females aged 2 years 11 months, 4 years 8 months, and 5 years 7 months, and three males aged 6 years 3 months, 5 years 3 months, and 1 year 9 months. Many of these patients exhibited Lisch nodules, a hallmark of NF1, which appear on the surface of the iris (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e2\u003c/span\u003eA). However, one child did not present with Lisch nodules, but rather with focal, flattened patches of pigment on the iris (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e2\u003c/span\u003eB). Although these symptoms concerning the iris did not show clear ocular complaints, these benign iris hamartomas are a key diagnostic feature, easily detectable via slit-lamp examination[\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]. In cases with orbital-facial involvement, associated ocular globe enlargement is often observed. Orbital MRI may demonstrate features such as enlarged eyeballs, abnormally thickened extraocular muscles, as shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e2\u003c/span\u003eD, bilateral optic nerve enlargement, thickening of the optic chiasm, and abnormal signal intensities in the brainstem and basal ganglia. These findings are highly suggestive of NF1 and align with observations reported in the existing literature[\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]. OCT images revealed choroidal hyperreflectivity and blurred optic disc margins can be detected in some patients (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e2\u003c/span\u003eC, E). Systemically, nearly all presented with caf\u0026eacute;-au-lait spots in the axillary, facial, or groin regions, further supporting the diagnosis of NF1[\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e].\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eAmong our cases, a 1-year-9-month-old child presented with a white cornea resulting from increased intraocular pressure. Initially diagnosed with glaucoma at a local hospital, further investigation revealed a family history of glaucoma in both the mother and grandfather. Upon referral to our hospital, further diagnostic evaluation, including ocular B-scan ultrasonography, revealed an enlarged eyeball with an abnormally elongated axial length, thickened optic nerve, and a band-like high echo within the vitreous cavity (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e2\u003c/span\u003eF, G). Subsequent genetic testing confirmed the diagnosis of NF1. This case underscores diverse ocular clinical manifestations and initial symptoms of NF1 and highlights the critical importance of thorough clinical evaluation and genetic testing. Clinicians should adopt a meticulous approach, carefully investigating beyond initial findings to uncover deeper systemic or genetic abnormalities that may underlie the ocular symptoms.\u003c/p\u003e \u003cp\u003eAdditionally, multiple patients developed optic pathway gliomas, which are observed in approximately 15% of NF1 patients[\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]. These gliomas sometimes led to strabismus and proptosis, necessitating neuroimaging and visual field testing for regular monitoring. Early intervention in symptomatic cases remains crucial to prevent visual loss.[\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e]\u003c/p\u003e \u003cp\u003eLiterature also suggests further ocular findings, including choroidal nodules and retinal vascular abnormalities, detectable using near-infrared reflectance imaging. OCT has provided detailed insights into retinal changes and assisted in managing optic gliomas, becoming essential for tracking ocular complications in pediatric NF1 patients.[\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e, \u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e]\u003c/p\u003e \u003cp\u003eBeyond ocular involvement, some patients in our cohort exhibited behavioral and cognitive deficits, common in NF1[\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. These systemic manifestations underscore multidisciplinary care's importance in effectively addressing ocular and non-ocular complications. Early diagnosis and comprehensive management are vital for optimizing outcomes in these patients.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003e3.3 Ocular Manifestations in NF2 and gene basis\u003c/h2\u003e \u003cp\u003eNF2 is caused by mutations in the NF2 gene on chromosome 22, which encodes Merlin, a protein that regulates cell proliferation and contact inhibition[\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e]. The disruption of this regulatory mechanism promotes uncontrolled cell growth and increases the likelihood of tumor formation. NF2 occurs in approximately 1 in 25,000 individuals worldwide, with about 50% of cases inherited through an autosomal dominant pattern, while the remaining cases arise from de novo mutations[\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e]. Although systemic manifestations such as bilateral vestibular schwannomas typically present in young adulthood, ocular symptoms often appear much earlier, particularly in pediatric patients, underscoring the importance of early screening.[\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e]\u003c/p\u003e \u003cp\u003eOur cohort included an 11-year 8-month-old female patient who had experienced bilateral visual decline for over three years before hearing loss in both ears. Her family history revealed that her brother had been previously diagnosed with NF2 and had passed away three years after brain tumor surgery. The patient presented with multiple caf\u0026eacute;-au-lait spots on her body and, during ophthalmologic evaluation, was found to have exotropia in the left eye, and mild cataracts in both eyes. And the epiretinal membrane (ERM) and macular edema as confirmed by OCT (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e3\u003c/span\u003eA). Her BCVA was 20/50 in both eyes, and no abnormalities were observed in the iris and other structures.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eThese findings are consistent with prior studies, which report that ocular manifestations of NF2, can appear in childhood and precede the onset of more severe systemic symptoms[\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]. Cataracts, observed in up to 80% of NF2 patients, may require surgical intervention to restore vision, especially as they progress. Retinal hamartomas and ERM, as identified in this patient, though less common, can significantly impair visual acuity and warrant continuous monitoring with OCT. The exotropia observed is aligned with previous reports of cranial nerve involvement in NF2, which may also lead to optic nerve sheath meningiomas or vestibular schwannomas affecting ocular motility. [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e]\u003c/p\u003e \u003cp\u003eAlthough ocular manifestations occur as the first sign in only 12% of NF2 cases, they often develop much earlier than systemic tumors, with some reports indicating onset as early as 5.6 years[\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]. Therefore, regular ophthalmologic follow-ups are crucial in identifying these early changes, especially in children with a family history of NF2. Timely detection and intervention can help manage vision loss and provide better outcomes for these patients.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003e3.4 \u003cb\u003eOcular Manifestations in VHL and Gene Basis\u003c/b\u003e\u003c/h2\u003e \u003cp\u003eVHL disease is a rare, autosomal dominant hereditary syndrome caused by mutations in the VHL tumor suppressor gene, which encodes a protein regulating cellular responses to hypoxia and angiogenesis by targeting the transcription factor HIF for degradation[\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. Mutations in the VHL gene result in abnormal angiogenesis and the development of various tumors, with retinal hemangioblastomas being the most common ocular manifestations associated with the condition with a prevalence ranging from 30\u0026ndash;58%[\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e, \u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIn our study, we included a 14-year-old and 2-month-old female patient who had previously undergone adenoma resection for a hemangioblastoma at our institution. Following her surgery, she was advised to visit the ophthalmology department. Upon examination, a clear retinal lesion consistent with a retinal hemangioblastoma was identified in the superior nasal quadrant of her right eye (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e3\u003c/span\u003eB). Fortunately, her visual acuity remained stable, and there were no signs of inflammation, choroidal detachment, or other complications. Our department promptly performed laser photocoagulation treatment on her right eye, and she has shown stability in her condition during regular follow-up visits.\u003c/p\u003e \u003cp\u003eIn addition to retinal hemangioblastomas, patients with VHL may present with other ocular manifestations, such as retinal cysts and choroidal hemangiomas[\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. Retinal hemangioblastomas are often the earliest manifestation of VHL, potentially leading to vision loss through exudation, hemorrhage, or retinal detachment. Therefore, early detection via fundoscopy and subsequent treatment, including laser or cryotherapy, is crucial for preserving visual function and preventing complications.\u003c/p\u003e \u003cp\u003eGiven the potential ocular involvement in VHL, it is essential for patients diagnosed with this condition by other specialties to undergo routine ophthalmic evaluations.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003e3.5 Ocular Manifestations in TSC and Gene Basis\u003c/h2\u003e \u003cp\u003eTSC is a genetic disorder characterized by multi-system hamartomas resulting from mutations in the TSC1 and TSC2 genes, leading to the overactivation of the mTOR signaling pathway and dysregulation of cell proliferation[\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e]. Typically diagnosed in early childhood or adolescence, TSC is a chronic, multisystemic disorder with age-dependent manifestations that pose challenges for lifelong surveillance. In some studies, epilepsy remains one of the main neurological challenges, with over 90% of cases manifesting in childhood[\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. The abnormal performance of the eye requires vigilance in monitoring, paralleling the broader systemic challenges.\u003c/p\u003e \u003cp\u003eRetinal hamartomas are the most common ocular feature in TSC, appearing as yellowish or calcified lesions. While typically asymptomatic, they may affect vision in rare cases, especially when lesions are located near the macula or optic disc.\u003c/p\u003e \u003cp\u003eIn our study, we included a 13-year-8-month-old female patient with a confirmed TSC1 mutation. She initially presented to the neurosurgery department with nausea and headache and was subsequently diagnosed with a subependymal giant cell astrocytoma with thickening bilateral orbital nerves, requiring neurosurgical intervention (Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e4\u003c/span\u003eA, B). Since the onset of systemic symptoms, her vision has been severely impaired, and limited to light perception. Preoperative evaluation in our department revealed bilateral pupil dilation, pale optic discs, and blurred disc margins (Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e4\u003c/span\u003eC-E). Postoperative examination showed no improvement in BCVA. While optic nerve edema had subsided, the optic discs remained pale (Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e4\u003c/span\u003eF). OCT revealed the disorganization of outer photoreceptor segments in both eyes, with a suspected hamartoma in the right eye (Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e4\u003c/span\u003eG-H). This case highlights the significant ocular complications associated with TSC1 mutations, particularly in the context of systemic manifestations and neurosurgical interventions.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eAdditionally, we included a TSC2 patient, a 5-year and 10-month-old male, who presented with vision decline. Whole-exome sequencing confirmed a TSC2 mutation, and upon examination, bilateral retinal hamartomas were identified (Fig.\u0026nbsp;\u003cspan refid=\"Fig10\" class=\"InternalRef\"\u003e5\u003c/span\u003eA-C). He underwent bilateral retinal laser photocoagulation, resulting in stable vision, with corrected visual acuity of 30/50 in the right eye and 20/50 in the left. Some TSC patients also exhibit choroidal depigmentation or other abnormalities, which can be observed during comprehensive ophthalmic exams[\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e, \u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e]. The clinical significance of these findings remains under investigation.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003e3.6 Cross-Mechanisms in Tumor Suppressor Genes Affecting Ocular Manifestations\u003c/h2\u003e \u003cp\u003eDysregulation of key signaling pathways, including E2F, Ras, mTOR, HIF-1α, and Hippo, was related to mutations in RB1, NF1, NF2, VHL, TSC1, and TSC2, contributing to abnormal cell growth, impaired apoptosis, disordered angiogenesis, and microenvironmental imbalances. Mutations in RB1, NF1, NF2, VHL, TSC1, and TSC2 play a significant role in these processes, and overlapping ocular manifestations may occur. The RB1 gene is involved in regulating the cell cycle, genomic stability, apoptosis, metabolism, and angiogenesis. Mutations in RB1 can activate the E2F pathway, driving the development of retinoblastoma, while its role in apoptosis is linked to the mTOR pathway[\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e, \u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e]. Similarly, TSC1/TSC2 mutations upregulate mTOR signaling, causing hamartomas and disrupting cellular metabolism[\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eNF1 and NF2 mutations impact the Ras and Hippo pathways, respectively, leading to schwannomas and optic gliomas[\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. Notably, NF2 mutations also affect cell adhesion and cytoskeletal stability, thereby maintaining tissue integrity[\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e]. VHL gene mutations impair the regulation of HIF-1α, promoting abnormal angiogenesis and contributing to the formation of RH[\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. Furthermore, the mTOR and HIF-1α pathways intersect under hypoxic conditions, exacerbating oxidative stress and driving further pathological changes[\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e]. Both VHL and TSC1/TSC2 are crucial regulators of vascular homeostasis and metabolic responses, playing a central role in the tumor microenvironment[\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e, \u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe Ras-PI3K-AKT-mTOR and interaction between mTOR and HIF are particularly important in regulating cell growth and tissue metabolism, while pathways such as Ras, mTOR, HIF-1α, and Hippo also modulate the tumor microvascular environment[\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e, \u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eDysregulation of these interconnected signaling pathways not only underpins the development of systemic and ocular tumors but also contributes to progressive ocular damage and retinal pathologies. These processes highlight the complex interplay between tumor suppressor genes, their downstream pathways, and their roles in ocular disease manifestation.\u003c/p\u003e \u003c/div\u003e"},{"header":"4. Discussion","content":"\u003cp\u003eThe ocular manifestations of tumor suppressor gene mutations in pediatric patients, particularly those associated with RB1, NF1, NF2, VHL, and TSC, are critical for early diagnosis and management of systemic diseases. These findings often precede other clinical symptoms, underscoring the importance of comprehensive pediatric ophthalmologic examinations.\u003c/p\u003e \u003cp\u003eIn this study, we presented a case of bilateral retinoblastoma diagnosed at three months of age, which recurred in one eye following treatment. This case, along with previous literature, highlights several important points: 1. Children with retinoblastoma in both eyes are at a higher risk of relapse; 2. Smaller infants with retinoblastoma are more likely to experience recurrence; 3. Long-term follow-up is crucial for all retinoblastoma patients.[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]\u003c/p\u003e \u003cp\u003eInterestingly, most cases in this study were not initially seen in the ophthalmology department; patients came to us for eye examinations after surgical or neurosurgical treatment. NF1 patients often exhibit distinctive ocular findings, such as Lisch nodules, which are pathognomonic and can be easily observed. These findings, along with the risk of optic pathway gliomas, underscore the need for routine ophthalmic evaluations. Our findings also highlight the importance of ongoing ocular assessments in TSC and VHL patients. For instance, retinal hemangioblastomas in VHL are often the first detectable signs and require early intervention to prevent complications like retinal detachment. Additionally, patients diagnosed with VHL in other specialties should receive regular eye evaluations. In TSC, retinal hamartomas serve as key diagnostic markers, reinforcing the need for routine eye examinations to facilitate early intervention for potential vision-threatening issues.\u003c/p\u003e \u003cp\u003eThis study has several limitations. First, the limited sample size (n\u0026thinsp;=\u0026thinsp;11) may restrict the generalizability of findings, particularly for rare genotypes like NF2 and VHL. Second, incomplete long-term follow-up data preclude definitive conclusions on disease progression and treatment outcomes. Third, as a single-center study, results may not reflect regional variations in genetic epidemiology or healthcare practices. Future research should prioritize multicenter collaborations to expand sample size, and include comprehensive longitudinal outcomes.\u003c/p\u003e \u003cp\u003eThis study emphasizes the importance of tumor suppressor gene expression in ocular manifestations. Even when initial symptoms may not present in the eye, they serve as critical warning signs for other healthcare providers. As ophthalmologists, we must remain vigilant not only to ocular findings but also to the systemic manifestations associated with these gene abnormalities. A multidisciplinary approach involving pediatric ophthalmologists, geneticists, and other specialists is essential. Regular ophthalmic follow-ups are crucial for monitoring disease progression and adjusting treatment strategies. Ultimately, early diagnosis and continuous ophthalmic monitoring, combined with advancements in genetic research and personalized medicine, are vital for preserving vision and managing systemic complications in children with mutations in tumor suppressor genes. Functional studies exploring the mTOR-HIF-1α axis in VHL/TSC-related angiogenesis may uncover new therapeutic targets. We believe the integration of targeted therapies and personalized treatment protocols based on genetic profiles holds promise for improving patient outcomes and quality of life.\u003c/p\u003e"},{"header":"5. Conclusion","content":"\u003cp\u003eOcular manifestations serve as critical early indicators for hereditary cancer syndromes linked to RB1, NF1, NF2, VHL, and TSC mutations. Regular ophthalmic evaluations, and genetic testing combined with multidisciplinary care, are essential for timely diagnosis and improved outcomes. Larger sample sizes and long-term follow-up data are required to validate the generalizability of our findings and develop more comprehensive diagnostic and treatment protocols.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003eRB1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003eretinoblastoma susceptibility gene\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003eNF1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003eneurofibromatosis type 1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003eVHL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003eVon Hippel-Lindau\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003eTSC\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003etuberous sclerosis complex\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003eRB\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003eretinoblastoma\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003epRb\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003eretinoblastoma protein\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003eRCC\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003erenal cell carcinoma\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003eRH\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003eretinal hemangiomas\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003eHIF\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003ehypoxia-inducible factor\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003emTOR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003emammalian target of the\u0026nbsp;rapamycin\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003eWES\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003ewhole-exome sequencing\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003eIVC\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003eintravenous chemotherapy\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003eNT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003enew tumor\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003eOCT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003eoptical coherence tomography\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003eERM\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 50%;\"\u003e\n \u003cp\u003eepiretinal membrane\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eFunding information:\u003c/strong\u003e This work was supported by the Natural Science Foundation of Hunan Province of China to Yu Tian (2022JJ80005), the Hunan Disabled Rehabilitation Association Foundation of China to Yu Tian (2023XK0224), and the Changsha Science and Technology Project of China to Yu Tian (kh2401012).\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eFunding information:\u003c/strong\u003e This work was supported by the Natural Science Foundation of Hunan Province of China to Yu Tian (2022JJ80005), the Hunan Disabled Rehabilitation Association Foundation of China to Yu Tian (2023XK0224), and the Changsha Science and Technology Project of China to Yu Tian (kh2401012).\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis study was conducted following the principles of the Declaration of Helsinki. Informed consent was obtained in writing from the parents or legal guardians of all participants before the procedure. The Ethics Committee of Hunan Children\u0026rsquo;s Hospital granted ethical approval (No. HCHLL-2022-76).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eClinical trial number: not applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for Publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll co-authors have given their approval for the final manuscript and consented to its publication.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare no competing interests.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003cstrong\u003eCRediT authorship contribution statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAoxiang Wang: Writing \u0026ndash; original draft, Investigation, Visualization, Formal analysis. Chanyuan Wang: Writing \u0026ndash; review \u0026amp; editing, Software, Methodology. \u0026nbsp;Wen Li: Data curation. Jing Qiao: Conceptualizations. Yulin Luo: Writing \u0026ndash; review \u0026amp; editing, Validation. Yu Tian: Writing \u0026ndash; review \u0026amp; editing, Supervision, Funding acquisition, Conceptualization.\u003c/p\u003e\n\n"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eJ. Zhang\u003cem\u003e et al.\u003c/em\u003e, \u0026quot;Germline Mutations in Predisposition Genes in Pediatric Cancer,\u0026quot; (in eng), \u003cem\u003eN Engl J Med, \u003c/em\u003evol. 373, no. 24, pp. 2336-2346, Dec 10 2015, doi: 10.1056/NEJMoa1508054.\u003c/li\u003e\n\u003cli\u003eH. Dimaras\u003cem\u003e et al.\u003c/em\u003e, \u0026quot;Retinoblastoma,\u0026quot; (in eng), \u003cem\u003eNat Rev Dis Primers, \u003c/em\u003evol. 1, p. 15021, Aug 27 2015, doi: 10.1038/nrdp.2015.21.\u003c/li\u003e\n\u003cli\u003eC. C. Cruz-G\u0026aacute;lvez, J. C. Ordaz-Favila, V. M. Villar-Calvo, M. E. Cancino-Marentes, and V. Bosch-Canto, \u0026quot;Retinoblastoma: Review and new insights,\u0026quot; (in eng), \u003cem\u003eFront Oncol, \u003c/em\u003evol. 12, p. 963780, 2022, doi: 10.3389/fonc.2022.963780.\u003c/li\u003e\n\u003cli\u003eY. Yao, X. Gu, X. Xu, S. Ge, and R. Jia, \u0026quot;Novel insights into RB1 mutation,\u0026quot; (in eng), \u003cem\u003eCancer Lett, \u003c/em\u003evol. 547, p. 215870, Oct 28 2022, doi: 10.1016/j.canlet.2022.215870.\u003c/li\u003e\n\u003cli\u003eT. M\u0026uuml;hlenberg\u003cem\u003e et al.\u003c/em\u003e, \u0026quot;KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy,\u0026quot; (in eng), \u003cem\u003eMol Cancer Ther, \u003c/em\u003evol. 18, no. 11, pp. 1985-1996, Nov 2019, doi: 10.1158/1535-7163.Mct-18-1224.\u003c/li\u003e\n\u003cli\u003eE. Uusitalo\u003cem\u003e et al.\u003c/em\u003e, \u0026quot;Incidence and Mortality of Neurofibromatosis: A Total Population Study in Finland,\u0026quot; \u003cem\u003eJournal of Investigative Dermatology, \u003c/em\u003evol. 135, no. 3, pp. 904-906, 2015/3/1, doi: 10.1038/jid.2014.465.\u003c/li\u003e\n\u003cli\u003eM. Nebbioso\u003cem\u003e et al.\u003c/em\u003e, \u0026quot;Neurofibromatosis Type 1: Ocular Electrophysiological and Perimetric Anomalies,\u0026quot; (in eng), \u003cem\u003eEye Brain, \u003c/em\u003evol. 12, pp. 119-127, 2020, doi: 10.2147/eb.S255184.\u003c/li\u003e\n\u003cli\u003eA. Romero-Titos, P. \u0026Aacute;lvarez-S\u0026aacute;nchez, F. M. H. Fern\u0026aacute;ndez, M. Castro-G\u0026oacute;mez, and B. B. Blasco, \u0026quot;Retinal astrocytic hamartoma: A rare ocular presentation in neurofibromatosis type 2,\u0026quot; (in eng), \u003cem\u003eJ Fr Ophtalmol, \u003c/em\u003evol. 46, no. 9, pp. e317-e320, Nov 2023, doi: 10.1016/j.jfo.2023.03.013.\u003c/li\u003e\n\u003cli\u003eD. A. Hilton and C. O. Hanemann, \u0026quot;Schwannomas and their pathogenesis,\u0026quot; (in eng), \u003cem\u003eBrain Pathol, \u003c/em\u003evol. 24, no. 3, pp. 205-20, Apr 2014, doi: 10.1111/bpa.12125.\u003c/li\u003e\n\u003cli\u003eA. B. Daniels\u003cem\u003e et al.\u003c/em\u003e, \u0026quot;Guidelines for surveillance of patients with von Hippel-Lindau disease: Consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance,\u0026quot; (in eng), \u003cem\u003eCancer, \u003c/em\u003evol. 129, no. 19, pp. 2927-2940, Oct 1 2023, doi: 10.1002/cncr.34896.\u003c/li\u003e\n\u003cli\u003eS. Mazumder, P. J. Higgins, and R. Samarakoon, \u0026quot;Downstream Targets of VHL/HIF-\u0026alpha; Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance,\u0026quot; (in eng), \u003cem\u003eCancers (Basel), \u003c/em\u003evol. 15, no. 4, Feb 19 2023, doi: 10.3390/cancers15041316.\u003c/li\u003e\n\u003cli\u003eS. Karimi, A. Arabi, T. Shahraki, and S. Safi, \u0026quot;Von Hippel-Lindau Disease and the Eye,\u0026quot; (in eng), \u003cem\u003eJ Ophthalmic Vis Res, \u003c/em\u003evol. 15, no. 1, pp. 78-94, Jan-Mar 2020, doi: 10.18502/jovr.v15i1.5950.\u003c/li\u003e\n\u003cli\u003eK. A. Orlova and P. B. Crino, \u0026quot;The tuberous sclerosis complex,\u0026quot; (in eng), \u003cem\u003eAnn N Y Acad Sci, \u003c/em\u003evol. 1184, pp. 87-105, Jan 2010, doi: 10.1111/j.1749-6632.2009.05117.x.\u003c/li\u003e\n\u003cli\u003eH. C. Lam\u003cem\u003e et al.\u003c/em\u003e, \u0026quot;p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis,\u0026quot; (in eng), \u003cem\u003eCancer Res, \u003c/em\u003evol. 77, no. 12, pp. 3255-3267, Jun 15 2017, doi: 10.1158/0008-5472.Can-16-2458.\u003c/li\u003e\n\u003cli\u003eP. B. Dias\u003cem\u003e et al.\u003c/em\u003e, \u0026quot;Optical coherence tomography detection of retinal neural loss in patients with tuberous sclerosis,\u0026quot; (in eng), \u003cem\u003eInt J Retina Vitreous, \u003c/em\u003evol. 10, no. 1, p. 15, Feb 4 2024, doi: 10.1186/s40942-024-00535-7.\u003c/li\u003e\n\u003cli\u003eL. Singh\u003cem\u003e et al.\u003c/em\u003e, \u0026quot;Epidemiology, Diagnosis and Genetics of Retinoblastoma: ICMR Consensus Guidelines,\u0026quot; (in eng), \u003cem\u003eIndian J Pediatr, \u003c/em\u003evol. 91, no. 11, pp. 1147-1156, Nov 2024, doi: 10.1007/s12098-024-05085-2.\u003c/li\u003e\n\u003cli\u003eR. Kaewkhaw and D. Rojanaporn, \u0026quot;Retinoblastoma: Etiology, Modeling, and Treatment,\u0026quot; (in eng), \u003cem\u003eCancers (Basel), \u003c/em\u003evol. 12, no. 8, Aug 16 2020, doi: 10.3390/cancers12082304.\u003c/li\u003e\n\u003cli\u003eO. Warda, Z. Naeem, K. A. Roelofs, M. S. Sagoo, and M. A. Reddy, \u0026quot;Retinoblastoma and vision,\u0026quot; (in eng), \u003cem\u003eEye (Lond), \u003c/em\u003evol. 37, no. 5, pp. 797-808, Apr 2023, doi: 10.1038/s41433-021-01845-y.\u003c/li\u003e\n\u003cli\u003eA. K. G\u0026uuml;nd\u0026uuml;z, I. Mirzayev, H. Din\u0026ccedil;aslan, and F. S. \u0026Ouml;zalp Ateş, \u0026quot;Recurrence and new tumor development after frontline intravenous chemotherapy for retinoblastoma: Risk factors and treatment results,\u0026quot; (in eng), \u003cem\u003eEur J Ophthalmol, \u003c/em\u003evol. 32, no. 3, pp. 1795-1803, May 2022, doi: 10.1177/11206721211023311.\u003c/li\u003e\n\u003cli\u003eT. C. Lee, N. I. Hayashi, I. J. Dunkel, K. Beaverson, D. Novetsky, and D. H. Abramson, \u0026quot;New retinoblastoma tumor formation in children initially treated with systemic carboplatin,\u0026quot; (in eng), \u003cem\u003eOphthalmology, \u003c/em\u003evol. 110, no. 10, pp. 1989-94; discussion 1994-5, Oct 2003, doi: 10.1016/s0161-6420(03)00669-9.\u003c/li\u003e\n\u003cli\u003eJ. Li\u003cem\u003e et al.\u003c/em\u003e, \u0026quot;Outcome of salvage intra-arterial chemotherapy for recurrent retinoblastoma,\u0026quot; (in eng), \u003cem\u003eEye (Lond), \u003c/em\u003evol. 36, no. 11, pp. 2106-2110, Nov 2022, doi: 10.1038/s41433-021-01693-w.\u003c/li\u003e\n\u003cli\u003eS. Kaliki, V. S. Vempuluru, Y. Priya, and A. Mohamed, \u0026quot;Risk factors for recurrent retinoblastoma after intravenous chemotherapy,\u0026quot; (in eng), \u003cem\u003eInt Ophthalmol, \u003c/em\u003evol. 41, no. 6, pp. 2033-2039, Jun 2021, doi: 10.1007/s10792-021-01759-4.\u003c/li\u003e\n\u003cli\u003eZ. X. Feng, J. Zhao, N. Zhang, M. Jin, and B. Gallie, \u0026quot;Adjuvant Chemotherapy Improves Survival for Children With Massive Choroidal Invasion of Retinoblastoma,\u0026quot; (in eng), \u003cem\u003eInvest Ophthalmol Vis Sci, \u003c/em\u003evol. 64, no. 11, p. 27, Aug 1 2023, doi: 10.1167/iovs.64.11.27.\u003c/li\u003e\n\u003cli\u003eR. Manukonda, R. V. Narayana, S. Kaliki, D. K. Mishra, and G. K. Vemuganti, \u0026quot;Emerging therapeutic targets for retinoblastoma,\u0026quot; (in eng), \u003cem\u003eExpert Opin Ther Targets, \u003c/em\u003evol. 26, no. 11, pp. 937-947, Nov 2022, doi: 10.1080/14728222.2022.2158812.\u003c/li\u003e\n\u003cli\u003eV. M. Riccardi, \u0026quot;Neurofibromatosis: past, present, and future,\u0026quot; (in eng), \u003cem\u003eN Engl J Med, \u003c/em\u003evol. 324, no. 18, pp. 1283-5, May 2 1991, doi: 10.1056/nejm199105023241812.\u003c/li\u003e\n\u003cli\u003eK. I. Ly and J. O. Blakeley, \u0026quot;The Diagnosis and Management of Neurofibromatosis Type 1,\u0026quot; (in eng), \u003cem\u003eMed Clin North Am, \u003c/em\u003evol. 103, no. 6, pp. 1035-1054, Nov 2019, doi: 10.1016/j.mcna.2019.07.004.\u003c/li\u003e\n\u003cli\u003eD. T. Miller, D. Freedenberg, E. Schorry, N. J. Ullrich, D. Viskochil, and B. R. Korf, \u0026quot;Health Supervision for Children With Neurofibromatosis Type 1,\u0026quot; (in eng), \u003cem\u003ePediatrics, \u003c/em\u003evol. 143, no. 5, May 2019, doi: 10.1542/peds.2019-0660.\u003c/li\u003e\n\u003cli\u003eB. Abdolrahimzadeh, D. C. Piraino, G. Albanese, F. Cruciani, and S. Rahimi, \u0026quot;Neurofibromatosis: an update of ophthalmic characteristics and applications of optical coherence tomography,\u0026quot; (in eng), \u003cem\u003eClin Ophthalmol, \u003c/em\u003evol. 10, pp. 851-60, 2016, doi: 10.2147/opth.S102830.\u003c/li\u003e\n\u003cli\u003eS. Abdolrahimzadeh, M. Formisano, F. Guglielmelli, S. Amodeo, M. C. Costa, and G. Scuderi, \u0026quot;Unusual Case of Indolent Choroidal Alterations Mimicking Neurofibromatosis Type 1,\u0026quot; (in eng), \u003cem\u003eCase Rep Ophthalmol, \u003c/em\u003evol. 11, no. 2, pp. 167-173, May-Aug 2020, doi: 10.1159/000507428.\u003c/li\u003e\n\u003cli\u003eK. H. Moon\u003cem\u003e et al.\u003c/em\u003e, \u0026quot;Differential Expression of NF2 in Neuroepithelial Compartments Is Necessary for Mammalian Eye Development,\u0026quot; (in eng), \u003cem\u003eDev Cell, \u003c/em\u003evol. 44, no. 1, pp. 13-28.e3, Jan 8 2018, doi: 10.1016/j.devcel.2017.11.011.\u003c/li\u003e\n\u003cli\u003eA. Plana-Pla, I. Bielsa-Marsol, and C. Carrato-Mo\u0026ntilde;ino, \u0026quot;Diagnostic and Prognostic Relevance of the Cutaneous Manifestations of Neurofibromatosis Type 2,\u0026quot; (in eng spa), \u003cem\u003eActas Dermosifiliogr, \u003c/em\u003evol. 108, no. 7, pp. 630-636, Sep 2017, doi: 10.1016/j.ad.2016.12.007. Manifestaciones cut\u0026aacute;neas de la neurofibromatosis tipo 2: inter\u0026eacute;s diagn\u0026oacute;stico y pron\u0026oacute;stico.\u003c/li\u003e\n\u003cli\u003eR. Tamura, \u0026quot;Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis,\u0026quot; (in eng), \u003cem\u003eInt J Mol Sci, \u003c/em\u003evol. 22, no. 11, May 29 2021, doi: 10.3390/ijms22115850.\u003c/li\u003e\n\u003cli\u003eD. Zhao\u003cem\u003e et al.\u003c/em\u003e, \u0026quot;iASPP is essential for HIF-1\u0026alpha; stabilization to promote angiogenesis and glycolysis via attenuating VHL-mediated protein degradation,\u0026quot; (in eng), \u003cem\u003eOncogene, \u003c/em\u003evol. 41, no. 13, pp. 1944-1958, Mar 2022, doi: 10.1038/s41388-022-02234-9.\u003c/li\u003e\n\u003cli\u003eO. Vorobichik Berar\u003cem\u003e et al.\u003c/em\u003e, \u0026quot;Mammalian target of rapamycin inhibitors for the treatment of astrocytic hamartoma in tuberous sclerosis complex (TSC),\u0026quot; (in eng), \u003cem\u003eGraefes Arch Clin Exp Ophthalmol, \u003c/em\u003evol. 260, no. 9, pp. 3061-3068, Sep 2022, doi: 10.1007/s00417-022-05585-x.\u003c/li\u003e\n\u003cli\u003eL. Licchetta\u003cem\u003e et al.\u003c/em\u003e, \u0026quot;Tuberous sclerosis complex in adulthood: focus on epilepsy prognosis,\u0026quot; (in eng), \u003cem\u003eEpilepsy Behav, \u003c/em\u003evol. 153, p. 109688, Apr 2024, doi: 10.1016/j.yebeh.2024.109688.\u003c/li\u003e\n\u003cli\u003eG. M. Bacci, S. Polizzi, F. Mari, V. Conti, R. Caputo, and R. Guerrini, \u0026quot;Atypical Ocular Coloboma in Tuberous Sclerosis-2: Report of Two Novel Cases,\u0026quot; (in eng), \u003cem\u003eJ Neuroophthalmol, \u003c/em\u003evol. 41, no. 3, pp. e363-e365, Sep 1 2021, doi: 10.1097/wno.0000000000001099.\u003c/li\u003e\n\u003cli\u003eJ. L. Berry, A. Polski, W. K. Cavenee, T. P. Dryja, A. L. Murphree, and B. L. Gallie, \u0026quot;The RB1 Story: Characterization and Cloning of the First Tumor Suppressor Gene,\u0026quot; (in eng), \u003cem\u003eGenes (Basel), \u003c/em\u003evol. 10, no. 11, Nov 1 2019, doi: 10.3390/genes10110879.\u003c/li\u003e\n\u003cli\u003eE. Le Rhun\u003cem\u003e et al.\u003c/em\u003e, \u0026quot;Molecular targeted therapy of glioblastoma,\u0026quot; (in eng), \u003cem\u003eCancer Treat Rev, \u003c/em\u003evol. 80, p. 101896, Nov 2019, doi: 10.1016/j.ctrv.2019.101896.\u003c/li\u003e\n\u003cli\u003eS. H. Baik\u003cem\u003e et al.\u003c/em\u003e, \u0026quot;A Breakdown in Metabolic Reprogramming Causes Microglia Dysfunction in Alzheimer\u0026apos;s Disease,\u0026quot; (in eng), \u003cem\u003eCell Metab, \u003c/em\u003evol. 30, no. 3, pp. 493-507.e6, Sep 3 2019, doi: 10.1016/j.cmet.2019.06.005.\u003c/li\u003e\n\u003cli\u003eH. Jiang, A. M. Li, and J. Ye, \u0026quot;The magic bullet: Niclosamide,\u0026quot; (in eng), \u003cem\u003eFront Oncol, \u003c/em\u003evol. 12, p. 1004978, 2022, doi: 10.3389/fonc.2022.1004978.\u003c/li\u003e\n\u003cli\u003eS. Chakraborty, M. Balan, A. Sabarwal, T. K. Choueiri, and S. Pal, \u0026quot;Metabolic reprogramming in renal cancer: Events of a metabolic disease,\u0026quot; (in eng), \u003cem\u003eBiochim Biophys Acta Rev Cancer, \u003c/em\u003evol. 1876, no. 1, p. 188559, Aug 2021, doi: 10.1016/j.bbcan.2021.188559.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"bmc-pediatrics","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bped","sideBox":"Learn more about [BMC Pediatrics](http://bmcpediatr.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/bped/default.aspx","title":"BMC Pediatrics","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"tumor suppressor genes, pediatric oncology, ocular manifestations, retina and uveal tumor, early diagnosis","lastPublishedDoi":"10.21203/rs.3.rs-5838014/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-5838014/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground:\u003c/h2\u003e \u003cp\u003eThis study explores ocular manifestations in children with mutations in key tumor suppressor genes (RB1, NF1, NF2, VHL, TSC1/2), which are linked to common pediatric hereditary cancer syndromes. Mutations in these genes often lead to ocular lesions, particularly in the retina and uveal tract, including the choroid and iris. The expression of these tumor suppressor gene mutations in the eye has been a topic of interest for ophthalmologists and other healthcare professionals. We have summarized the ocular presentations of these common tumor suppressor gene mutations in pediatric patients.\u003c/p\u003e\u003ch2\u003eMethods:\u003c/h2\u003e \u003cp\u003eWe reviewed 11 representative case reports, documenting in detail the ocular manifestations and progression of each case. These case studies were analyzed in conjunction with a detailed search of the relevant literature to identify specific ocular features associated with each tumor suppressor gene mutation, as well as potential underlying genetic mechanisms.\u003c/p\u003e\u003ch2\u003eResults:\u003c/h2\u003e \u003cp\u003eOur review indicates that children with mutations in RB1, NF1, NF2, VHL, and TSC1/2 exhibit a diverse range of ocular manifestations, with the specific features varying depending on the type of mutation. Early detection of ocular symptoms is crucial, as it allows for prompt intervention, significantly improving both visual and systemic outcomes. Additionally, these genetic mutations are frequently associated with systemic syndromes, emphasizing the importance of recognizing ocular symptoms and providing timely ophthalmic care and follow-up for early diagnosis and effective management. This highlights the critical role of a multidisciplinary healthcare team in managing these cases.\u003c/p\u003e\u003ch2\u003eConclusions:\u003c/h2\u003e \u003cp\u003eThis study highlights the significance of regular ophthalmic evaluations for children with hereditary cancer syndromes associated with tumor suppressor gene mutations. Early detection and timely intervention are essential for preserving vision and supporting overall development. Given the complexity of these conditions, it is vital for both ophthalmology and other medical specialties to closely collaborate and prioritize these patients. Future research should focus on larger cohort studies and the development of tailored strategies for managing specific gene mutations.\u003c/p\u003e","manuscriptTitle":"Ocular Manifestations in Pediatric Tumor Suppressor Gene Mutations: A Case Series and Literature Review of RB1, NF1, NF2, VHL, and TSC","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-03-31 12:08:22","doi":"10.21203/rs.3.rs-5838014/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2025-04-04T01:56:58+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-03-31T17:17:26+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"204012068036145133284952130583537335955","date":"2025-03-28T07:33:13+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-03-28T07:28:38+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-03-27T02:35:21+00:00","index":"","fulltext":""},{"type":"submitted","content":"BMC Pediatrics","date":"2025-03-26T09:31:51+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"bmc-pediatrics","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bped","sideBox":"Learn more about [BMC Pediatrics](http://bmcpediatr.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/bped/default.aspx","title":"BMC Pediatrics","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"01bba556-940a-4f7e-967d-e5f83703b8aa","owner":[],"postedDate":"March 31st, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2025-05-12T16:06:17+00:00","versionOfRecord":{"articleIdentity":"rs-5838014","link":"https://doi.org/10.1186/s12887-025-05694-6","journal":{"identity":"bmc-pediatrics","isVorOnly":false,"title":"BMC Pediatrics"},"publishedOn":"2025-05-10 15:57:49","publishedOnDateReadable":"May 10th, 2025"},"versionCreatedAt":"2025-03-31 12:08:22","video":"","vorDoi":"10.1186/s12887-025-05694-6","vorDoiUrl":"https://doi.org/10.1186/s12887-025-05694-6","workflowStages":[]},"version":"v1","identity":"rs-5838014","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-5838014","identity":"rs-5838014","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}